Introduction {#s1}
============

Gas exchange, the essential function of the lung, depends on the production of a sufficient number of functional alveoli to provide surface area for gas exchange ([@bib12]; [@bib73]; [@bib16]). Elucidating the molecular mechanisms by which alveoli are formed remains a major unresolved question. Lung branching morphogenesis is followed by the construction of primary saccules at the distal end of the branching lung tree. The smooth wall of the primary saccules is further modified by the generation of secondary crests or septa, which divide the saccules into alveoli. As a result, the surface area of gas exchange is greatly increased to meet the high demand of oxygen consumption in terrestrial, warm-blooded animals. Uncovering the molecular basis of alveolar development will also provide insight into diseases that affect the alveoli. For instance, bronchopulmonary dysplasia (BPD), in which maturation of alveoli fails to occur ([@bib62]), is prevalent in premature babies. Moreover, insults to the lung in adult life such as infectious diseases or chronic obstructive pulmonary disease (COPD) can lead to destruction of alveoli and respiratory failure ([@bib50]). A mechanistic understanding of alveolar formation will offer new therapies to regenerate alveolar surface area and treat diseases caused by loss of alveoli ([@bib55]).

The most important step in alveolar development is the formation of epithelial folds (secondary septa) within the saccules, in which thin and flat alveolar type I (AT1) cells cover a core of myofibroblasts, connective tissue and capillaries ([@bib10]). Compared to AT1 cells, alveolar type II (AT2) cells contribute to a much smaller surface area for gas exchange but they play a central role in lung expansion after birth by secreting pulmonary surfactants. During the first 2--3 days of postnatal life, the smooth wall (the primary septa) of saccules in wild-type mouse lungs is modified by epithelial folding, which is termed rudimentary secondary crests or septa, to increase the surface area for gas exchange. Secondary septa consist of alveolar type I cells that cover a core of myofibroblasts, connective tissue and capillaries ([@bib16]). Elongation of secondary septa is associated with deposition of elastin by myofibroblasts and maturation of capillaries. At around postnatal day 5, many of the primary saccules have been subdivided into alveoli by secondary septation although this process will continue for another 25 days and beyond. Secondary septa formation greatly increases the surface area for gas exchange in mammals and is the most critical event during alveolar formation.

The current model posits that interstitial fibroblasts respond to platelet-derived growth factor (PDGF) signaling and migrate to the prospective secondary septa to form alveolar myofibroblasts ([@bib16]), which express smooth muscle actin (SMA). It is postulated that myofibroblast migration and elastin deposition by myofibroblasts provide the driving force for secondary septa elongation. However, the molecular mechanisms that control cell migration remain poorly understood. Similarly, the molecular processes that mediate interactions between alveolar epithelial cells and prospective myofibroblasts during secondary septa formation are unknown. Importantly, whether alveolar epithelial cells also play an active role in promoting alveologenesis has not been determined. New insight into these key issues is pivotal to our mechanistic understanding of alveolar formation.

We reasoned that signaling pathways that control the actomyosin cytoskeleton likely play a crucial role in cell migration and interaction during secondary septa formation. The planar cell polarity (PCP; also known as tissue polarity) pathway ([@bib67]; [@bib15]; [@bib18]; [@bib13]; [@bib23]; [@bib30]; [@bib63]; [@bib78]; [@bib7]; [@bib51]) has been shown to regulate the actomyosin cytoskeleton. In this study, we employed PCP signaling as a tool to reveal the molecular basis of secondary septation and alveolar formation in mice. PCP (a non-canonical Wnt pathway) is a fundamental, conserved mechanism for polarizing a field of cells within the plane of an epithelial cell sheet and is essential in many tissues. PCP signaling is initiated by the binding of Wnt ligands to the Frizzled (Fz) receptors ([@bib70]). The signal is relayed by a set of core PCP components that include cytoplasmic and membrane proteins. The outcome of PCP signaling is an altered actomyosin cytoskeleton that is local and is associated with polarized cellular function in a field of cells. The role of PCP components in lung development has been described ([@bib76]; [@bib52]), but its molecular mechanisms are unknown. Other well-characterized systems that require PCP include convergent extension in neural tube closure, hair cell orientation in the cochlea of the inner ear, hair follicle orientation, and motile cilia positioning in the trachea. It is somewhat surprising that, in each system, the molecular mechanisms that mediate PCP's effects on cellular behavior are largely underexplored.

Our work described in this report has discovered a new mechanism of PCP signaling in which a *Wnt5a--Ror2--Vangl2* axis controls tissue patterning through regulating cellular properties and not tissue polarity. Specifically, PCP signaling controls PDGF ligand secretion from alveolar type I and type II cells, instructs cell shape change of alveolar type I cells, and regulates myofibroblast migration. All of these are mediated though the actomyosin cytoskeleton. These novel insights significantly extend our current understanding of alveolar formation and PCP signaling in tissue patterning. They not only provide a new conceptual framework for understanding how the alveolus is generated during development but also have a major impact on advancing disease mechanisms caused by alveolar malformation or destruction.

Results {#s2}
=======

Inactivation of *Vangl2* in the distal lung epithelium disrupts alveolar formation {#s2-1}
----------------------------------------------------------------------------------

To understand how PCP pathway components control alveolar formation, we eliminated PCP signaling in the distal lung epithelium by generating *Vangl2^f/f^; Sox9^Cre/+^* mice. A floxed (f) allele of *Vangl2* (*Vangl2^f^*) ([@bib64]) was converted into a null allele through strong expression of Cre from the *Sox9* locus (*Sox9-Cre*) ([@bib2]) in the SOX9^+^ distal lung epithelium. During canalicular (16.5--17.5 *days post coitus* (*dpc*)) and saccular development (17.5 *dpc*--postnatal (P) day 4), following the completion of branching morphogenesis, airspace at the terminal bronchioles is subdivided to form saccules ([@bib60]). Lined by alveolar type I and type II cells, saccules function as the primitive gas-exchange unit. As expected, VANGL2 protein was barely detectable in the distal epithelium of *Vangl2^f/f^; Sox9^Cre/+^* lungs by 18.5 *dpc* (shortly before birth), while VANGL2 expression in the lung mesenchyme and elsewhere was unaffected ([Figure 1---figure supplements 1](#fig1s1){ref-type="fig"}, [2](#fig1s2){ref-type="fig"} and [3](#fig1s3){ref-type="fig"}). Loss of *Vangl2* abolishes PCP signaling since *Vangl2* encodes a four-pass transmembrane protein and is an essential component of mammalian PCP signaling ([@bib4]).

*Vangl2^f/f^; Sox9^Cre/+^* animals were born alive and cannot be distinguished from their wild-type littermates by their outer appearance or activity at birth ([Figure 1---figure supplement 3](#fig1s3){ref-type="fig"}). However, at postnatal day 2, *Vangl2^f/f^; Sox9^Cre/+^* mice can be identified by their slightly diminished body size. The reduced size and activity in these mutants became more pronounced as postnatal development proceeded. Mortality was observed in *Vangl2^f/f^; Sox9^Cre/+^* mice at various time points postnatally, especially between postnatal day 3 and 7 (mostly after day 4/5). Interestingly, a small number of *Vangl2^f/f^; Sox9^Cre/+^* mice survived beyond postnatal day 7. *Vangl2*-deficient lungs consisted of enlarged saccules ([Figure 1A](#fig1){ref-type="fig"}) and failed to generate alveoli ([Figure 1B](#fig1){ref-type="fig"}). These results establish an essential role of *Vangl2* in alveolar formation (traditionally defined as P5-25 in mice) during lung development.

![*Vangl2* is required in both the lung epithelium and mesenchyme for alveolar formation.\
(**A**) Surface view of dissected lungs from wild-type and *Vangl2^f/f^; Sox9^Cre/+^* mice at different postnatal (P) stages as indicated. Enlarged saccules were discerned in *Vangl2^f/f^; Sox9^Cre/+^* lungs at P3 and their size increased significantly as postnatal lung development proceeded. (**B**) Hematoxylin and eosin-stained lung sections of wild-type and *Vangl2^f/f^; Sox9^Cre/+^* mice at different postnatal stages. Histological analysis confirmed the presence of enlarged saccules in *Vangl2*-deficient lungs starting at P3. Arrows point to rudimentary secondary septa. (**C**) Transmission electron micrographs of lungs from wild-type and *Vangl2^f/f^; Sox9^Cre/+^* mice at P3. Rudimentary secondary septa (arrows), in which the alveolar type I (AT1) cells encased myofibroblasts and blood vessels, were seen in control but not *Vangl2*-deficient lungs. (**D**) Measurement of the mean linear intercept (MLI) in wild-type and *Vangl2^f/f^; Sox9^Cre/+^* lungs (n = 3 for each group). The MLI was increased in *Vangl2*-deficient lungs, starting at P3. (**E**) Hematoxylin and eosin-stained lung sections of wild-type and *Vangl2^f/f^; Pdgfra^Cre/+^* mice at different postnatal stages. Enlarged saccules were detected in *Vangl2^f/f^; Pdgfra^Cre/+^* lungs at P3 and their size increased significantly as postnatal lung development proceeded. (**F**) Surface view of dissected lungs from wild-type and *Vangl2^f/f^; Pdgfra^Cre/+^* mice at P5. Larger saccules were found in *Vangl2* mutant lungs induced by *Pdgfra^Cre^*. (**G**) Measurement of the MLI in wild-type and *Vangl2^f/f^; Pdgfra^Cre/+^* lungs (n = 3 for each group). The MLI was increased in *Vangl2*-deficient lungs, starting at P5. (**H**) Hematoxylin and eosin-stained lung sections of wild-type and *Vangl2^f/f^; Dermo1^Cre/+^* mice at P5. Larger saccules were found in *Vangl2* mutant lungs induced by *Dermo1^Cre^*. (**I**) Measurement of the MLI in wild-type and *Vangl2^f/f^; Dermo1^Cre/+^* lungs (n = 3 for each group). The MLI was increased in *Vangl2*-deficient lungs. All values are mean ± SEM. (\*) p\<0.05; (\*\*) p\<0.01; ns, not significant (unpaired Student's *t*-test).](elife-53688-fig1){#fig1}

Of note, the mammalian genome contains two homologs (*Vangl1* and *Vangl2*) of fly *Van Gogh (Van)/strabismus. Vangl1*-deficient mice that are homozygous for a gene-trapped null allele of *Vangl1* (*Vangl1^gt^*) ([@bib66]) are fully viable without apparent lung phenotypes and reproduce with normal litter size. This suggests that *Vangl1* plays a minor role in alveolar formation and loss of *Vangl1* is compensated by *Vangl2* in alveologenesis. Of note, we failed to recover live *Vangl1^gt/gt^; Vangl2^f/f^; Sox9^Cre/+^* mice postnatally. Hence, our study on alveologenesis has focused on *Vangl2*. Surprisingly, the widely used *Shh^Cre^* ([@bib26]), which drives Cre expression along the entire developing lung epithelium, failed to effectively eliminate VANGL2 ([Figure 1---figure supplement 4](#fig1s4){ref-type="fig"}). *Vangl1^gt/gt^; Vangl2^f/f^; Shh^Cre/+^* mice were fully viable and fertile without apparent phenotypes ([Figure 1---figure supplement 4](#fig1s4){ref-type="fig"}). In the literature, a hypomorphic (reduced function) allele of *Vangl2*, *Vangl2^Lp^* (*loop tail*) ([@bib44]), has been reported in several studies. Homozygous *Vangl2^Lp/Lp^* mice die in utero due to neural tube defects while heterozygous *Vangl2^Lp/+^* mice display mild alveolar defects in adults but minimal alveolar phenotypes at postnatal day 7 ([@bib52]). Thus, *Vangl2^Lp/+^* mice are unsuitable for studying the molecular mechanisms of alveolar formation. This would require complete removal of *Vangl2* function in a select compartment (*e.g.*, the lung epithelium, mesenchyme or others) through conditional inactivation of *Vangl2^f^* using various mouse Cre lines. Our approach thus enables us to reveal how PCP signaling regulates alveolar development.

To determine the cause of neonatal lethality in *Vangl2^f/f^; Sox9^Cre/+^* mice, we examined lungs from control and *Vangl2^f/f^; Sox9^Cre/+^* mice at different time points postnatally. We noticed that the primary septa in control lungs became visibly thinner during the first three days of postnatal life likely due to flattening of AT1 cells ([Figure 1---figure supplement 5](#fig1s5){ref-type="fig"}). The thickness of the primary septa subsequently increased, presumably reflecting cell proliferation and structural changes in the mesenchyme and folding of AT1 cells ([Figure 1---figure supplement 5](#fig1s5){ref-type="fig"}), which is correlated with the progression of alveolar development ([@bib75]). No obvious difference in the gross morphology of the lungs was noticed between control and *Vangl2^f/f^; Sox9^Cre/+^* mice prior to postnatal day 3 ([Figure 1A](#fig1){ref-type="fig"}). Histological analysis of control and *Vangl2^f/f^; Sox9^Cre/+^* lungs showed no apparent difference prior to postnatal day 3 ([Figure 1B](#fig1){ref-type="fig"}). Loss of *Vangl2* mediated by *Sox9-Cre* thus does not disrupt branching morphogenesis or saccule formation ([Figure 1---figure supplement 3](#fig1s3){ref-type="fig"}).

At postnatal day 3, enlarged saccules were discerned in *Vangl2^f/f^; Sox9^Cre/+^* lungs in comparison with controls under a dissecting microscope ([Figure 1A](#fig1){ref-type="fig"}). This finding was confirmed by morphological analysis of dissected lungs using light microscopy ([Figure 1B](#fig1){ref-type="fig"}). Transmission electron microscopy (TEM) of control and *Vangl2^f/f^; Sox9^Cre/+^* lungs revealed lack of rudimentary secondary septa (arrows) in the mutant lungs ([Figure 1C](#fig1){ref-type="fig"}). No apparent defects in other organs were found in *Vangl2^f/f^; Sox9^Cre/+^* mice ([Figure 1---figure supplement 6](#fig1s6){ref-type="fig"}). The primary septa in *Vangl2^f/f^; Sox9^Cre/+^* lungs underwent a similar thinning process in the first three days of postnatal life. However, the primary septa in mutant lungs failed to engender subsequent modification and retained a relatively thin appearance ([Figure 1B](#fig1){ref-type="fig"}). These results suggest that loss of PCP signaling in the distal lung cells has a profound influence on the normal progression and development of the primary septa to generate secondary septa. Only a very small number of primordial secondary septa could be detected in *Vangl2^f/f^; Sox9^Cre/+^* lungs. As a result, *Vangl2*-deficient lungs contained enlarged saccules ([Figure 1B](#fig1){ref-type="fig"}, [Figure 1---figure supplement 7](#fig1s7){ref-type="fig"}) with an increased mean linear intercept (MLI, a measure of air space size) ([Figure 1D](#fig1){ref-type="fig"}). Disruption of secondary septa formation in the absence of PCP signaling in the distal lung epithelium likely led to respiratory failure and neonatal lethality.

Inactivation of *Vangl2* in interstitial fibroblasts/myofibroblasts disrupts alveolar formation, resembling loss of epithelial *Vangl2* {#s2-2}
---------------------------------------------------------------------------------------------------------------------------------------

Most studies on PCP signaling have focused on how this pathway controls collective cell behavior in epithelial sheets. Whether PCP signaling functions in mesenchymal cells is underexplored. To determine if PCP signaling is required in the lung mesenchyme for alveolar formation, we generated *Vangl2^f/f^; Dermo1^Cre/+^* and *Vangl2^f/f^; Pdgfra^Cre/+^* mice. *Dermo1* (*Twist2*) is broadly expressed in mesenchymal cells while *Pdgfra*, which encodes a receptor for the platelet-derived growth factor A (PDGFA), is expressed in interstitial fibroblasts and induces smooth muscle actin (SMA) expression, a hallmark of myofibroblasts. Thus, Cre expression from the *Dermo1* locus (*Dermo1^Cre^*) ([@bib77]) would eliminate *Vangl2* in most mesenchymal cells whereas Cre expression from the *Pdgfra* locus (*Pdgfra^Cre^*) ([@bib56]) would inactivate *Vangl2* in interstitial fibroblasts/myofibroblasts and disrupt PCP signaling.

We found that *Vangl2^f/f^; Dermo1^Cre/+^* and *Vangl2^f/f^; Pdgfra^Cre/+^* mice displayed lung phenotypes ([Figure 1E, F, G, H and I](#fig1){ref-type="fig"}) resembling those in *Vangl2^f/f^; Sox9^Cre/+^* mice. Secondary septa failed to form in *Vangl2^f/f^; Dermo1^Cre/+^* or *Vangl2^f/f^; Pdgfra^Cre/+^* mice, saccules were enlarged with an increased mean linear intercept, and many of the mutants failed to survive beyond postnatal day 7 ([Figure 1E, F, G, H and I](#fig1){ref-type="fig"}). We noticed that more *Vangl2^f/f^; Pdgfra^Cre/+^* survivors with less severe alveolar defects were observed than *Vangl2^f/f^; Sox9^Cre/+^* survivors. This could be due to differential Cre activity or differential contributions of epithelial and mesenchymal PCP signaling to alveolar formation. Loss of one copy of *Vangl1* did not exacerbate the lung phenotypes in *Vangl2^f/f^; Pdgfra^Cre/+^* mice, highlighting the major role of *Vangl2* in interstitial fibroblasts/myofibroblasts during alveolar formation. We conclude that PCP signaling operates in both the lung epithelium and mesenchyme and each process is essential for secondary septa formation by controlling distinct aspects of alveologenesis.

Alveolar defects in mice carrying *Ror2*-deficient lung epithelium or interstitial fibroblasts/myofibroblasts recapitulate phenotypes caused by *Vangl2* loss in the corresponding compartment {#s2-3}
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

To reveal the signaling cascade that controls *Vangl2* function and subsequently alveolar formation, we tested the role of *Ror2* (receptor tyrosine kinase-like orphan receptor 2), which has been implicated in PCP signaling in other tissues ([@bib27]). To this end, we generated *Ror2^f/f^; Sox9^Cre/+^* mice and anticipated that a floxed allele of *Ror2* (*Ror2^f^*) ([@bib27]) would be converted to a null allele in the distal lung epithelium by *Sox9-Cre*. If ROR2 is responsible for mediating VANGL2 activity, we predict that loss of *Ror2* in the distal lung epithelium in *Ror2^f/f^; Sox9^Cre/+^* mice would result in alveolar defects similar to those in *Vangl2^f/f^; Sox9^Cre/+^* mice. Indeed, *Ror2^f/f^; Sox9^Cre/+^* mice displayed neonatal lethality and their lungs failed to produce secondary septa ([Figure 2A and B](#fig2){ref-type="fig"}). A detailed phenotypic analysis ([Figure 2A and B](#fig2){ref-type="fig"}) confirmed the similarity of lung phenotypes between *Ror2^f/f^; Sox9^Cre/+^* and *Vangl2^f/f^; Sox9^Cre/+^* mice.

![*Ror2* is required in both the lung epithelium and mesenchyme while *Wnt5a* is required in the lung mesenchyme for alveolar formation.\
(**A**) Hematoxylin and eosin-stained lung sections of wild-type and *Ror2^f/f^; Sox9^Cre/+^* mice at different postnatal (P) stages. Histological analysis revealed the presence of enlarged saccules starting at P3 in *Ror2*-deficient lungs. (**B**) Surface view of dissected lungs from wild-type and *Ror2^f/f^; Sox9^Cre/+^* mice at P5. Larger saccules were found in *Ror2* mutant lungs induced by *Sox9^Cre^* and the MLI was correspondingly increased in *Ror2*-deficient lungs. (**C**) Hematoxylin and eosin-stained lung sections of wild-type and *Ror2^f/f^; Pdgfra^Cre/+^* mice at P5. Histological analysis confirmed the presence of enlarged saccules starting at P3 in *Ror2*-deficient lungs. (**D**) Surface view of dissected lungs from wild-type and *Ror2^f/f^; Pdgfra^Cre/+^* mice at P5. Larger saccules were found in *Ror2* mutant lungs induced by *Pdgfra^Cre^* with an increased MLI. (**E**) Hematoxylin and eosin-stained lung sections of wild-type and *Porcn^f/f^; Pdgfra^Cre/+^* mice at P12. Larger saccules were found in *Porcn* mutant lungs induced by *Pdgfra-Cre* with an increased MLI. (**F**) Hematoxylin and eosin-stained lung sections of wild-type and *Wnt5a^f/f^; Tbx4^Cre/+^* mice at P10. Larger saccules were found in *Wnt5a* mutant lungs induced by *Tbx4-Cre* with an increased MLI. (**G**) Combined in situ hybridization (PLISH)/immunohistochemistry on lung sections of *Pdgfra^H2BGFP/+^* mice to examine *Wnt5a* expression. *Wnt5a* mRNA was mainly detected in myofibroblasts (H2BGFP^+^) and not in the lung epithelium. (**H**) Schematic diagram of a *Wnt5a--Ror2--Vangl2* axis that functions in both the lung epithelium and mesenchyme to regulate alveologenesis. (**I**) Schematic diagram of the temporal sequence of fibroblast/myofibroblast proliferation, differentiation and migration.](elife-53688-fig2){#fig2}

We also produced *Ror2^f/f^; Pdgfra^Cre/+^* mice to remove *Ror2* in lung interstitial fibroblasts/myofibroblasts. As predicted by our model of a *Ror2--Vangl2* cascade, these mice died postnatally due to alveolar defects ([Figure 2C and D](#fig2){ref-type="fig"}), resembling phenotypes observed in *Vangl2^f/f^; Pdgfra^Cre/+^* mice. Taken together, these studies established a key role of *Ror2* in activating *Vangl2* in either alveolar epithelial cells or mesenchymal myofibroblasts. The downstream events mediated by *Ror2--Vangl2* are critical for secondary septa formation and alveolar formation.

Mesenchymal *Wnt5a* signaling to lung epithelium and mesenchyme is essential for alveolar development {#s2-4}
-----------------------------------------------------------------------------------------------------

A key question in further understanding how PCP signaling controls alveolar development is to uncover the signals that trigger a *Ror2--Vangl2* cascade. Several non-canonical Wnt ligands are expressed in the lungs ([@bib36]) and are candidates for activating a *Ror2--Vangl2* axis. We first manipulated the activity of *Porcupine* (*Porcn*) in the lung, which is required for the release of all WNT proteins from *Wnt*-producing cells ([@bib14]; [@bib42]). Consistent with the involvement of *Wnt* signaling in alveolar development, treatment of neonatal mice with Wnt-C59 ([@bib53]) or LGK974 (WNT-974) ([@bib41]), inhibitors of PORCUPINE, resulted in alveolar defects ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). Moreover, inactivation of *Porcn* in the lung mesenchyme by creating *Porcn^f/f^; Dermo1^Cre/+^* mice or in lung myofibroblasts by generating *Porcn^f/f^; Pdgfra^Cre/+^* mice also led to alveolar defects ([Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}, [Figure 2E](#fig2){ref-type="fig"}). In this setting, a floxed allele of *Porcn* (*Porcn^f^*) ([@bib40]) was removed by *Dermo1-Cre* or *Pdgfra-Cre*. These results support the notion that Wnt signals in the lung mesenchyme initiate PCP signaling for alveolar development.

Among the Wnt ligands, WNT5A is a likely candidate in activating a *Ror2--Vangl2* cascade in the lung mesenchyme. *Wnt5a* transcripts were detected in fibroblasts and myofibroblasts ([Figure 2---figure supplement 3](#fig2s3){ref-type="fig"}) and a very small number of alveolar epithelial cells by single cell RNA-Seq analysis of postnatal lungs ([@bib24]). Moreover, *Wnt5a*-deficient lungs exhibit a shortened trachea ([@bib35]; [@bib31]), consistent with defective PCP signaling. Whether *Wnt5a* controls PCP signaling during alveolar development is unknown. We first performed PLISH (proximity ligation in situ hybridization) ([@bib47]) on lungs from *Pdgfra^H2BGFP^* mice ([@bib25]) to examine the expression patterns of *Wnt5a* in postnatal lungs. Expression of the H2B-GFP fusion protein in the nucleus of *Pdgfra*-expressing cells (*Pdgfra^H2BGFP^*) unambiguously marked myofibroblasts. We found that *Wnt5a* mRNA was mainly expressed in myofibroblasts and barely any signal was detected in the lung epithelium ([Figure 2G](#fig2){ref-type="fig"}).

To test the role of *Wnt5a* in activating a *Ror2--Vangl2* cascade, we initially utilized *Sox9-Cre*, *Pdgfra-Cre* and *Dermo1-Cre* to convert a floxed allele of *Wnt5a* (*Wnt5a^f^*) ([@bib58]) into a null allele. Unfortunately, *Wnt5a^f/f^; Sox9^Cre/+^*, *Wnt5a^f/f^; Pdgfra^Cre/+^* and *Wnt5a^f/f^; Dermo1^Cre/+^* mice all died soon after birth due to craniofacial defects. The perinatal lethality prevented us from analyzing alveolar defects in these animals. To circumvent this problem, we employed *Tbx4-Cre* ([@bib34]) to inactivate *Wnt5a* selectively in the lung mesenchyme but not the mesenchyme of other tissues. *Wnt5a^f/f^; Tbx4^Cre/+^* mice were born alive but many displayed a smaller body size at postnatal day 4 or 5. Phenotypic analysis of *Wnt5a^f/f^; Tbx4^Cre/+^* lungs revealed defective alveolar formation ([Figure 2F](#fig2){ref-type="fig"}) albeit the alveolar defects were not as pervasive as those caused by loss of *Ror2* or *Vangl2*. In other experimental settings, we have found that *Tbx4-Cre* is less efficient in conditional gene inactivation in comparison to other Cre lines.

Taken together, our genetic studies have established a *Wnt5a--Ror2--Vangl2* axis in controlling alveolar formation ([Figure 2H](#fig2){ref-type="fig"}). In this process, mesenchymal *Wnt5a* triggers a *Ror2/Vangl2*--mediated cascade in both lung epithelium and mesenchyme.

In many studies where PCP signaling controls the collective cell behavior of epithelial sheets, PCP components display asymmetric distribution within individual epithelial cells. This is proposed to underlie the coordination between epithelial cells through organizing the cytoskeleton along the same axis among individual cells. We thus examined VANGL2 distribution in either lung epithelial cells or mesenchymal myofibroblasts. To our surprise, we found no apparent asymmetric localization of VANGL2 in alveolar type I cells, alveolar type II cells or myofibroblasts ([Figure 2---figure supplement 4](#fig2s4){ref-type="fig"}). This led to our new model in which a *Wnt5a--Ror2--Vangl2* axis controls cellular properties of individual lung cells regardless of asymmetric activation of PCP components. We speculate that this cascade sets in motion PDGF signaling from alveolar type I and type II cells, morphological changes of alveolar type I cells and migration of myofibroblasts, all of which are required for alveolar formation. We will test these hypotheses in subsequent sections.

Loss of epithelial *Vangl2* leads to defective PDGF signal reception in mesenchymal myofibroblasts {#s2-5}
--------------------------------------------------------------------------------------------------

Lack of secondary septa in *Vangl2^f/f^; Sox9^Cre/+^* mice was associated with thin primary septa. This prompted us to investigate whether proliferation and function of myofibroblasts were affected in the absence of epithelial PCP signaling in *Vangl2^f/f^; Sox9^Cre/+^* lungs. In wild-type lungs, fibroblast proliferation can be detected at P0; this is followed by SMA expression at P2/3 and subsequent migration while proliferation continues ([Figure 2I](#fig2){ref-type="fig"}). Indeed, we found that interstitial fibroblasts that expressed PDGFRA failed to proliferate as revealed by reduced EdU incorporation in *Vangl2^f/f^; Pdgfra^H2BGFP/+^; Sox9^Cre/+^* mice in comparison with *Pdgfra^H2BGFP/+^* mice (controls) ([Figure 3A](#fig3){ref-type="fig"}, [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). Myofibroblasts were labeled by H2BGFP. Moreover, myofibroblasts (SMA^+^) in *Vangl2^f/f^; Sox9^Cre/+^* lungs failed to migrate to the prospective sites of secondary septa formation ([Figure 3B](#fig3){ref-type="fig"}). Decreased myofibroblast proliferation first appeared at postnatal day 2 when PDGFRA^+^ interstitial fibroblasts started to express SMA and became myofibroblasts. This suggests that expansion of fibroblasts prior to SMA expression and migration was disrupted in the absence of epithelial *Vangl2*. By postnatal day 3, the number of PDGFRA^+^ interstitial fibroblasts had vastly decreased in the mutant lungs ([Figure 3C](#fig3){ref-type="fig"}). This was associated with a major reduction in SMA^+^ cells. Myofibroblasts secrete elastin and collagen, which play an important role in promoting secondary septa formation. As expected, both SMA and elastin production was significantly curtailed in *Vangl2^f/f^; Sox9^Cre/+^* lungs ([Figure 3D](#fig3){ref-type="fig"}).

![*Vangl2* is required for PDGF ligand trafficking/release from PDGF-producing cells and subsequently PDGF signal reception.\
(**A**) Immunostaining of lung sections collected from *Pdgfra^H2BGFP/+^* (control) and *Vangl2^f/f^; Sox9^Cre/+^; Pdgfra^H2BGFP/+^* mice injected with EdU at postnatal (P) day 5. Lung epithelial cells were distinguished by NKX2.1 staining while myofibroblasts were marked by H2B-GFP from the *Pdgfra* locus (*Pdgfra^H2BGFP^*). The number of EdU^+^ cells was reduced in *Vangl2^f/f^; Sox9^Cre/+^; Pdgfra^H2BGFP/+^* lungs compared to controls. (**B**) Immunostaining of lung sections collected from control and *Vangl2^f/f^; Sox9^Cre/+^* mice at P5. Organization of the cytoskeleton and stress fibers was disrupted and SMA at the prospective sites of secondary septation was sparse in *Vangl2*-deficient lungs. (**C**) Quantification of myofibroblast proliferation in *Pdgfra^H2BGFP/+^* (control) and *Vangl2^f/f^; Sox9^Cre/+^; Pdgfra^H2BGFP/+^* lungs at P2 and P5. The rate of myofibroblast proliferation was calculated as the ratio of the number of EdU^+^ myofibroblasts (EdU^+^H2BGFP^+^) to the number of myofibroblasts (H2BGFP^+^). An apparent reduction in the percentage of proliferating myofibroblasts was detected in *Vangl2^f/f^; Sox9^Cre/+^; Pdgfra^H2BGFP/+^* lungs compared to controls (n = 3 for each group) at P2 and P5. (**D**) qPCR analysis of *Acta2* (*SMA*) and *Elastin* in control and *Vangl2^f/f^; Sox9^Cre/+^* lungs at P3. The mRNA levels of *Acta2* and *Elastin* were significantly reduced in the absence of epithelial *Vangl2* induced by *Sox9-Cre* (n = 3 for each group). (**E**) Immunostaining of lung sections collected from *Pdgfa^ex4COIN/+^; Sox2^Cre/+^* mice at P2. *β-galactosidase* (*LacZ*) was induced in PDGFA-producing cells by *Sox2-Cre*. LacZ-staining (blue) was followed by immunostaining against HOPX (marker for AT1 cells) and SPC (marker for AT2 cells). LacZ-positive cells also expressed either HOPX or SPC. The number of AT1 or AT2 cells that harbored either high or low PDGFA (LacZ) was counted. (**F**) LacZ-staining (blue) of lung sections collected from *Pdgfa^ex4COIN/+^; Sox9^Cre/+^* (control) and *Vangl2^f/f^; Pdgfa^ex4COIN/+^; Sox9^Cre/+^* mice at P2. The slides were counterstained with eosin (red). No difference in the intensity of LacZ (+) cells in the lung was found in these two mouse lines. The mRNA levels of *Pdgfa* in control and mutant lungs were determined by qPCR. (**G**) Immunostaining of lung sections collected from control and *Vangl2^f/f^; Sox9^Cre/+^* mice at P3. No difference in PDGFRA expression levels in individual myofibroblasts was noted between control and *Vangl2^f/f^; Sox9^Cre/+^* lungs. (**H**) Immunostaining of lung sections collected from control and *Vangl2^f/f^; Sox9^Cre/+^* mice at P3. A significant reduction in the levels of phosphorylated (p) PDGFRA in individual myofibroblasts was found in *Vangl2^f/f^; Sox9^Cre/+^* lungs compared to controls. (**I**) Western blot analysis of cell lysates and supernatants from control and *Vangl1^gt/gt^; Vangl2^--/--^* cells lentivirally transduced with PDGFA-expressing constructs. The amount of PDGFA released into the media was significantly reduced in *Vangl1^gt/gt^; Vangl2^--/--^* cells compared to controls (n = 3 for each group). GAPDH served as a loading control. We noticed that the amount of secreted proteins (normalized to the cell number) from *Vangl1/2* mutant cells was reduced compared to controls. This suggests a general defect in protein processing/secretion in the absence of *Vangl1/2*. In this case, it is possible that other secreted ligands could also impact alveolar development. (**J**) Immunostaining of controls and *Vangl1^gt/gt^; Vangl2^--/--^* cells lentivirally transduced with PDGFA-expressing constructs. Endoplasmic reticulum (ER) was marked by mEmerald-ER-5. (**K**) Hematoxylin and eosin-stained lung sections of wild-type and *Vangl1^gt/gt^; Vangl2^f/f^; Sftpc^CreER/+^* mice injected with tamoxifen and collected at P10. Enlarged saccules were found in *Vangl1^gt/gt^; Vangl2^f/f^; Sftpc^CreER/+^* lungs in comparison with controls. (**L**) Immunostaining of controls and *Vangl1^gt/gt^; Vangl2^--/--^* cells. The Golgi stacks were dispersed in *Vangl1^gt/gt^; Vangl2^--/--^* cells compared to controls. Golgi was marked by mEmerald-Golgi-7. (**M**) Transmission electron micrographs of lungs from wild-type and *Vangl2^f/f^; Sox9^Cre/+^* mice at P3. Cellular extension (arrow) from alveolar type II cells to myofibroblasts was observed in control lungs but were absent in *Vangl2^f/f^; Sox9^Cre/+^* lungs. (**N**) Schematic diagram of a positive feedback loop between WNT5A and PDGF to generate a pool of fibroblasts/myofibroblasts for alveologenesis. All values are mean ± SEM. (\*) p\<0.05; (\*\*) p\<0.01; (\*\*\*) p\<0.001; ns, not significant (unpaired Student's *t*-test).](elife-53688-fig3){#fig3}

Given the reciprocal interaction between the lung epithelium and mesenchyme, we speculate that aberrant myofibroblast development in *Vangl2^f/f^; Sox9^Cre/+^* lungs stems from malfunction of the lung epithelium. We first tested whether perturbation of pathways that signal from the lung epithelium to the mesenchyme would have caused anomalous alveolar formation in *Vangl2^f/f^; Sox9^Cre/+^* mice and found that PDGF signaling was disrupted in myofibroblasts in these animals. PDGFA is produced primarily in alveolar type I and type II cells and signals to *Pdgfra*-expressing fibroblasts/myofibroblasts ([@bib17]; [@bib22]) to regulate their proliferation and migration. While loss of either *Pdgfa* ([@bib8]; [@bib39]) or *Pdgfra* ([@bib65]) can result in loss of secondary septa ([@bib48]), we found no difference in PDGFA ligand production between control and *Vangl2^f/f^; Sox9^Cre/+^* lungs by both qPCR analysis and in situ hybridization. This conclusion was substantiated by a PDGFA reporter mouse line (*Pdgfa^ex4COIN^*) ([@bib3]) that faithfully recapitulates the spatial and temporal expression of *Pdgfa* since no reliable PDGFA antibody is available to detect endogenous PDGFA in tissues ([@bib22]; [@bib3]). In *Pdgfa^ex4COIN/+^; Sox2^Cre/+^* mice, Cre recombinase was broadly expressed and activated *β-galactosidase* (*lacZ*) expression (from the *Pdgfa^ex4COIN^* allele) in *Pdgfa*-expressing cells, including AT1 (HOPX^+^) and AT2 (SPC^+^) cells ([Figure 3E](#fig3){ref-type="fig"}). *LacZ* expression in *Pdgfa*-expressing epithelial cells is indicative of PDGFA levels. We found that PDGFA was expressed more frequently in AT1 cells than AT2 cells and PDGFA expression levels were higher in AT1 cells than AT2 cells ([Figure 3E](#fig3){ref-type="fig"}), consistent with single-cell RNA-Seq data ([@bib71]). We generated *Vangl2^f/f^; Pdgfa^ex4COIN/+^; Sox9^Cre/+^* to examine the effects of epithelial VANGL2 on PDGFA expression. PDGFA displayed a similar pattern and intensity between control and *Vangl2*-deficient lungs ([Figure 3F](#fig3){ref-type="fig"}), consistent with no reduction in *Pdgfa* transcript levels in the absence of *Vangl2* ([Figure 3F](#fig3){ref-type="fig"}). These results pointed to defective PDGF ligand trafficking, secretion or delivery in *Vangl2^f/f^; Sox9^Cre/+^* lungs after the PDGF ligand is made. It also predicts that PDGF fails to transduce its signal to mesenchymal myofibroblasts of *Vangl2^f/f^; Sox9^Cre/+^* lungs.

Consistent with our model, while the levels of PDGFRA in a single myofibroblast were unaffected ([Figure 3G](#fig3){ref-type="fig"}), phosphorylation of PDGFRA in individual myofibroblasts upon PDGFA ligand binding was significantly reduced in *Vangl2^f/f^; Sox9^Cre/+^* lungs ([Figure 3H](#fig3){ref-type="fig"}, [Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}). In addition, activation of the downstream kinases, such as AKT (a serine-threonine kinase) ([@bib19]), was drastically diminished in *Vangl2^f/f^; Sox9^Cre/+^* lungs in comparison with controls by immunostaining ([Figure 3---figure supplement 3](#fig3s3){ref-type="fig"}). Disrupted PDGF signal transduction in myofibroblasts led to reduced proliferation and migration. These findings support our model in which the PDGFA ligand produced in *Vangl2*-deficient alveolar epithelial cells fails to transduce its signal to mesenchymal myofibroblasts.

Alveolar epithelial cells lacking VANGL2 fail to present the PDGF ligand to mesenchymal myofibroblasts {#s2-6}
------------------------------------------------------------------------------------------------------

Our results indicate that loss of PCP signaling in alveolar epithelial cells disrupts their ability to transduce the PDGF signal to myofibroblasts in the mesenchyme. We envision that either the PDGF ligand failed to reach the cell surface of alveolar type I/II cells or failed to be delivered to target cells. To gain insight into this issue, we performed RNA-Seq analysis ([@bib28]) of control and *Vangl2^f/f^; Sox9^Cre/+^* lungs collected at P2 and P5. Interestingly, pathways that regulate vesicular transport were perturbed in the mutant lungs (details below), suggesting their role in PDGF secretion. To explore this idea, we assayed intracellular trafficking and secretion of PDGFA in control and *Vangl1/2*-deficient cells. Control and *Vangl1/2*-deficient cells were derived from control and *Vangl1^gt/gt^; Vangl2^--/--^* embryos and subsequently lentivirally transduced with constructs that encode a fusion protein of PDGFA and 3xFLAG or GFP. Using this assay, we determined the amount of PDGFA-3xFLAG released from control and *Vangl1/2*-deficient cells. PDGFA-3xFLAG in the media incubated with *Vangl1/2*-deficient cells was significantly reduced ([Figure 3I](#fig3){ref-type="fig"}). These findings are consistent with a failure in vesicular transport and ligand release of PDGFA without *Vangl1/2*. Indeed, we found that the intracellular levels of PDGFA-GFP were increased in *Vangl1/2*-deficient cells ([Figure 3J](#fig3){ref-type="fig"}, [Figure 3---figure supplement 4](#fig3s4){ref-type="fig"}).

Consistent with our model in which the PDGF ligand fails to be released from alveolar epithelial cells in the absence of *Vangl1/2*, inactivation of *Vangl1/2* in alveolar type II cells (Surfactant protein C \[SP-C or SPC\]^+^ encoded by *Sftpc*) led to alveolar defects. We generated *Vangl1^gt/gt^; Vangl2^f/f^; Sftpc^CreER/+^* mice and administered tamoxifen to these animals at P2. Activation of CreER by tamoxifen in SPC^+^ cells ([@bib37]) induced *Vangl2* removal. Analysis of lungs at P10 revealed areas of defective alveolar development that was associated with loss of *Vangl1/2* ([Figure 3K](#fig3){ref-type="fig"}, [Figure 3---figure supplement 5](#fig3s5){ref-type="fig"}). This supports a critical role of *Vangl1/2* in alveolar type II cells during alveologenesis.

We also discovered that the structure of the Golgi apparatus was altered in *Vangl1/2*-deficient cells. Compared to control cells in which the Golgi apparatus was properly polarized inside the cells, the Golgi stacks were dispersed in *Vangl1/2*-deficient cells ([Figure 3L](#fig3){ref-type="fig"}). We speculate that loss of the proper organization of the Golgi apparatus could contribute to disruption of the secretory pathways including PDGF ligand secretion.

Alveolar type II cells make direct cell-cell contacts with myofibroblasts via cellular processes that pass through the basement membrane ([Figure 3M](#fig3){ref-type="fig"}; [@bib11]; [@bib1]). Such cell-cell contacts could facilitate PDGF signaling as supported by recent studies in which most, if not all, major signaling pathways are shown to require cell-cell contacts for ligand-receptor interactions and signal transduction ([@bib32]; [@bib33]). In this scenario, ablation of PCP signaling in alveolar epithelial cells would affect the actomyosin cytoskeleton, a common output of PCP signaling, and consequently either the formation or function of cellular processes that are required for transducing the PDGF signal. Interestingly, TEM studies revealed loss of cellular processes from alveolar type II cells in *Vangl2^f/f^; Sox9^Cre/+^* lungs, which were no longer in direct contact with myofibroblasts ([Figure 3M](#fig3){ref-type="fig"}).

Taken together, our studies support a model in which alveolar type I and type II cells utilize a *Wnt5a--Ror2--Vangl2* cascade to control PDGF ligand trafficking and release and contribute to secondary septa formation. We surmise that these effects are mediated by the actomyosin cytoskeleton.

WNT5A and PDGF forms a positive feedback loop to generate a pool of fibroblasts/myofibroblasts required for alveologenesis {#s2-7}
--------------------------------------------------------------------------------------------------------------------------

In our model, a *Wnt5a--Ror2--Vangl2* cascade operates in both the epithelial and mesenchymal compartments. We investigated how these signaling events are coordinated during postnatal lung development. We found that phosphorylation of PDGFRA in individual myofibroblasts upon PDGFA ligand binding was reduced in *Wnt5a^f/f^; Tbx4^Cre/+^* lungs ([Figure 3---figure supplement 6](#fig3s6){ref-type="fig"}), while the levels of PDGFRA were unaffected ([Figure 3---figure supplement 6](#fig3s6){ref-type="fig"}). Moreover, elimination of mesenchymal *Wnt* signaling (including WNT5A secretion from fibroblasts) prior to alveologenesis in *Porcn^f/f^; Dermo1^Cre/+^* lungs led to reduced PDGF signal transduction without affecting PDGF ligand production or differentiation of alveolar type I and type II cells ([Figure 3---figure supplement 7](#fig3s7){ref-type="fig"}). This suggests that loss of mesenchymal *Wnt5a* compromises PDGF signal reception but not ligand production in fibroblasts/myofibroblasts. Conversely, loss of PDGF ligand resulted in depletion of WNT5A-producing fibroblasts/myofibroblasts and a reduction in *Wnt5a* transcript levels ([Figure 3---figure supplement 8](#fig3s8){ref-type="fig"}). These results support a positive feedback loop between WNT5A and PDGFA to generate an adequate number of fibroblasts/myofibroblasts required for alveologenesis ([Figure 3N](#fig3){ref-type="fig"}).

Components and regulators of the actomyosin cytoskeleton and vesicular transport show differential expression in *Vangl2* and *Ror2* mutant lungs by RNA-Seq analysis {#s2-8}
---------------------------------------------------------------------------------------------------------------------------------------------------------------------

We performed bulk RNA-Seq analysis of control and *Vangl2^f/f^; Sox9^Cre/+^* lungs collected at P2 and P5. Our phenotypic analysis has revealed a major effect of epithelial PCP signaling on myofibroblasts and perhaps other lung cell types as well. While it would be ideal to use sorted lung cells for RNA-Seq, it would be difficult to sort myofibroblasts away from airway smooth muscle cells and vascular smooth muscle cells since they express a similar set of markers. As expected, *Pdgfra* expression was downregulated in *Vangl2^f/f^; Sox9^Cre/+^* lungs while *Pdgfa* expression was not reduced. Several other pathways that are perturbed were identified ([Figure 4A and B](#fig4){ref-type="fig"}, [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). They include actomyosin cytoskeleton signaling, Wnt/β-catenin signaling, LXR/RXR signaling, CXCR4 signaling, CDK5 signaling, Toll-like receptor signaling and acute phase response signaling.

![*Vangl2* and *Ror2* regulate similar pathways.\
(**A--D**) Pathway analysis of transcriptomes derived from RNA-Seq of control, *Vangl2^f/f^; Sox9^Cre/+^*, and *Ror2^f/f^; Sox9^Cre/+^* lungs at postnatal (P) day 2 and 5 (n = 3 for each group). The top 25 enriched terms in GO (gene ontology) biological processes were shown. Loss of *Vangl2* or *Ror2* revealed changes in similar pathways, suggesting that *Vangl2* and *Ror2* function in the same pathway. (**E**) Heatmap of selected mouse genes from control and *Vangl2^f/f^; Sox9^Cre/+^* lungs at P5. Loss of epithelial *Vangl2* in mouse lungs activated these genes. Interestingly, they are known to be elevated in lungs of human emphysema patients and are biomarkers for emphysema.](elife-53688-fig4){#fig4}

We also performed RNA-Seq analysis on control and *Ror2^f/f^; Sox9^Cre/+^* lungs collected at P2 and P5 ([Figure 4C and D](#fig4){ref-type="fig"}). We expect that many changes in transcriptional responses would follow a similar trend in lungs deficient in epithelial *Vangl2* or *Ror2*, if *Ror2* is responsible for mediating *Vangl2* activity. Indeed, loss of *Vangl2* and *Ror2* showed similar changes in many pathways, affirming the genetic studies in which they function in the same axis.

*Vangl2*-deficient interstitial fibroblasts/myofibroblasts have disorganized actomyosin cytoskeletons and are defective in migration assays {#s2-9}
-------------------------------------------------------------------------------------------------------------------------------------------

We found that myofibroblast proliferation was also diminished in *Vangl2^f/f^; Pdgfra^Cre/+^* lungs but only at later stages of postnatal development while the initial expansion of fibroblasts/myofibroblasts was unaffected ([Figure 5A](#fig5){ref-type="fig"}). This is in contrast to defective fibroblast/myofibroblast expansion in *Vangl2^f/f^; Sox9^Cre/+^* lungs ([Figure 3C](#fig3){ref-type="fig"}). These results suggest that the primary role of mesenchymal PCP signaling is to control myofibroblast migration and function while epithelial PCP signaling plays a key role in the initial expansion of fibroblasts/myofibroblasts. Both SMA and elastin production was significantly reduced in *Vangl2^f/f^; Pdgfra^Cre/+^* lungs ([Figure 5B](#fig5){ref-type="fig"}). It is expected that failure of myofibroblast migration to the prospective site of secondary septation deprived them of receiving the PDGF ligand for proliferation. It is interesting to note that myofibroblasts send out cellular extensions to form a network of myofibroblasts after expansion of the fibroblast/myofibroblast population ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). In this process, VANGL2 was found to colocalize with SMA on these cellular extensions, suggesting a critical role of PCP signaling in controlling motility of myofibroblasts ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}).

![*Vangl2* regulates the cytoskeleton of myofibroblasts and their migration.\
(**A**) Quantification of myofibroblast proliferation in control and *Vangl2^f/f^; Pdgfra^Cre/+^* lungs at postnatal (P) day 3 and 5. The rate of myofibroblast proliferation was calculated as the ratio of the number of EdU^+^ myofibroblasts (EdU^+^PDGFRA^+^) to the number of myofibroblasts (PDGFRA^+^). An apparent reduction in the percentage of proliferating myofibroblasts was detected in *Vangl2^f/f^; Pdgfra^Cre/+^* lungs compared to controls (n = 3 for each group) at P5 but not at P3. (**B**) qPCR analysis of *Acta2* (*SMA*) and *Elastin* in control and *Vangl2^f/f^; Pdgfra^Cre/+^* lungs at P5. The mRNA levels of *Acta2* and *Elastin* were significantly reduced in the absence of *Vangl2* in myofibroblasts (n = 3 for each group). (**C**) Immunostaining of lung sections collected from control and *Vangl2^f/f^; Pdgfra^Cre/+^* mice at P5. The actomyosin cytoskeleton (stained by phalloidin) failed to organize around the prospective sites of secondary septa formation in *Vangl2^f/f^; Pdgfra^Cre/+^* lungs. In addition, smooth muscle actin (SMA) levels were significantly reduced and did not form stress fibers at the prospective sites of secondary septation. Arrows point to rudimentary secondary septa in control lungs. (**D**) Immunostaining of lung sections collected from control and *Vangl2^f/f^; Pdgfra^Cre/+^* mice at P0 and P5. Migration of myofibroblasts (PDGFRA^+^/SMA^+^) to the prospective sites of secondary septa failed to occur in the mutant lungs. (**E**) Wound recovery assays to assess the migratory ability of myofibroblasts derived from control and *Vangl2^f/f^; Pdgfra^Cre/+^* lungs. Within 36--48 hr, the wound area has been populated by migrating myofibroblasts derived from control lungs. By contrast, few myofibroblasts from *Vangl2^f/f^; Pdgfra^Cre/+^* lungs reached the wound area within the same time frame. (**F**) Quantification of wound recovery by myofibroblasts derived from control and *Vangl2^f/f^; Pdgfra^Cre/+^* lungs within 36--48 hr (n = 3 for each group). These results imply that mesenchymal *Vangl2* controls subsequent myofibroblast proliferation after the initial expansion or the migration defect exerts a secondary effect on myofibroblast proliferation or both. All values are mean ± SEM. (\*\*\*) p\<0.001 (unpaired Student's *t*-test).](elife-53688-fig5){#fig5}

We examined the actomyosin cytoskeleton in *Vangl2*-deficient myofibroblasts from *Vangl2^f/f^; Pdgfra^Cre/+^* lungs in comparison with control myofibroblasts. Phalloidin staining of F-actin (filamentous) revealed a disorganized actomyosin cytoskeleton and smooth muscle actin failed to produce organized stress fibers in mutant myofibroblasts ([Figure 5C](#fig5){ref-type="fig"}). We also analyzed fibroblast/myofibroblast distribution in *Vangl2^f/f^; Pdgfra^Cre/+^* lungs at P0 and P5 ([Figure 5D](#fig5){ref-type="fig"}). We found no difference in the distribution of PDGFRA^+^ fibroblasts at P0. However, at P5 while PDGFRA^+^/SMA^+^ myofibroblasts had migrated to the prospective sites of secondary septa in control lungs, PDGFRA^+^/SMA^+^ cells in the mutant lungs stayed in the primary septa.

These results predict that migration of *Vangl2*-deficient myofibroblasts would be compromised. To test this idea, we isolated myofibroblasts from control and *Vangl2^f/f^; Pdgfra^Cre/+^* lungs and seeded them onto the migration chamber. The rate of myofibroblast migration into the cell-free area was measured. While control myofibroblasts occupied the cell-free area after 36--48 hr, only scant *Vangl2*-deficient myofibroblasts were detected in the cell-free area during this time period ([Figure 5E and F](#fig5){ref-type="fig"}). This indicates that the mobility of myofibroblasts was compromised due to loss of PCP signaling in these cells. Reduced myofibroblast proliferation and migration thus underlies defective alveolar development in *Vangl2^f/f^; Pdgfra^Cre/+^* mice.

Alveolar type I cells devoid of VANGL2 are associated with disrupted cytoskeletons and fail to encase myofibroblasts necessary for secondary septa formation {#s2-10}
------------------------------------------------------------------------------------------------------------------------------------------------------------

Abnormal secondary septation in *Vangl2^f/f^; Sox9^Cre/+^* lungs due to loss of epithelial *Vangl2* suggests that the primary defect originates from faulty alveolar epithelial cells. This is in contrast to the traditional view of secondary septa formation in which the main driving force of septa formation is derived from myofibroblast migration and elastin deposition by myofibroblasts ([@bib16]). Having established a critical role of alveolar type I and type II cells in PDGF secretion during alveologenesis, we assessed the function of *Vangl2* in alveolar type I cells during alveolar formation. We conjectured that abrogated PCP signaling in alveolar type I cells would perturb the actomyosin cytoskeleton and impair their ability to adopt the cell shape necessary for encasing myofibroblasts during secondary septation. To validate this model, we initially used phalloidin to label F-actin and examined the actomyosin cytoskeleton in alveolar type I cells of control and *Vangl2^f/f^; Sox9^Cre/+^* lungs. Due to the extended morphology of alveolar type I cells, it was very difficult to obtain a clear view of the actomyosin cytoskeleton. We then searched for other markers for the actomyosin cytoskeleton and found that phosphorylated Cofilin and LIM-kinase (LIMK) were significantly increased in *Vangl2*-deficient alveolar type I cells, compared to controls ([Figure 6A, B and D](#fig6){ref-type="fig"}). Phosphorylation of Cofilin by LIMK inhibited its ability to depolymerize actin, leading to a failure in actin bundle remodeling ([Figure 6F](#fig6){ref-type="fig"}). This would generate disorganized stress fibers in *Vangl2*-deficient AT1 cells.

![*Vangl2* controls the cytoskeleton of alveolar type I cells, their cell shape changes and their ability in forming alveolospheres and new alveoli.\
(**A, B, D**) Immunostaining of lung sections collected from *Sox9^Cre/+^; ROSA26^mTmG/+^* (control) and *Vangl2^f/f^; Sox9^Cre/+^; ROSA26^mTmG/+^* mice at postnatal (P) day 3 and 5. GFP from the *ROSA26* locus (*ROSA26^mTmG^*) was activated in both alveolar type I (AT1) and type II (AT2) cells which could be distinguished by their morphology. The levels of phosphorylated (p) Cofilin and LIMK were significantly reduced in AT1 cells in control lungs by P5. By contrast, p-Cofilin and p-LIMK persisted in AT1 cells in *Vangl2^f/f^; Sox9^Cre/+^; ROSA26^mTmG/+^* lungs. (**C, E**) Immunostaining of lung sections collected from *Sox9^Cre/+^; Pdgfra^H2BGFP/+^* (control) and *Vangl2^f/f^; Sox9^Cre/+^; Pdgfra^H2BGFP/+^* mice at P3 and P5. Cell shape change of AT1 cells (T1α^+^) was observed in control lungs at the prospective sites of secondary septation to encase myofibroblasts (H2BGFP^+^) (myo) that had migrated toward AT1 cells. AT1 cells in *Vangl2^f/f^; Sox9^Cre/+^; Pdgfra^H2BGFP/+^* lungs failed to undergo similar morphological changes. (**F**) Schematic diagram of a *Vangl2*-initiated signaling cascade that leads to phosphorylation of Cofilin and actin remodeling. (**G**) Immunostaining of alveolospheres derived from control and *Vangl1^gt/gt^; Vangl2^f/f^; Sftpc^CreER/+^; ROSA26^mTmG/+^* mice injected with tamoxifen. Both SPC^+^ and HOPX^+^ cells were found in alveolospheres derived from control and *Vangl1^gt/gt^; Vangl2^f/f^; Sftpc^CreER/+^; ROSA26^mTmG/+^* mice despite a difference in size and organization. (**H**) Quantification of the percentage of large (cross-sectional area \>0.06mm^2^), medium (cross-sectional area between 0.015mm^2^ and 0.06mm^2^) and small (cross-sectional area \<0.015mm^2^) alveolospheres derived from control and *Vangl1^gt/gt^; Vangl2^f/f^; Sftpc^CreER/+^; ROSA26^mTmG/+^* mice (n = 5 for each group). The percentage of large alveolospheres derived from *Vangl1^gt/gt^; Vangl2^f/f^; Sftpc^CreER/+^; ROSA26^mTmG/+^* mice was reduced. (**I**) Hematoxylin and eosin-stained lung sections of wild-type and *Vangl1^gt/gt^; Vangl2^f/f^; Aqp5^CreER/+^; ROSA26^tdTomato/+^* mice injected with tamoxifen and collected at P7. Enlarged saccules were found in *Vangl1^gt/gt^; Vangl2^f/f^; Aqp5^CreER/+^; ROSA26^tdTomato/+^* lungs with an increased MLI in comparison with controls (n = 3 for each group). (**J**) Immunostaining of lung sections collected from *Sftpc^CreER/+^; ROSA26^mTmG/+^* (control) and *Vangl1^gt/gt^; Vangl2^f/f^; Sftpc^CreER/+^; ROSA26^mTmG/+^* mice injected with tamoxifen and treated with bleomycin. Lungs were harvested at 30 days post-bleomycin administration. In control lungs, GFP-labeled AT2 cells proliferated and differentiated into AT1 cells to form new alveoli. By contrast, fewer alveoli were produced in *Vangl1^gt/gt^; Vangl2^f/f^; Sftpc^CreER/+^; ROSA26^mTmG/+^* lungs. (**K**) Quantification of the percentage of large (cross-sectional area \>0.6mm^2^), medium (cross-sectional area between 0.2mm^2^ and 0.6mm^2^) and small (cross-sectional area \<0.2mm^2^) alveoli derived from *Sftpc^CreER/+^; ROSA26^mTmG/+^* (control) and *Vangl1^gt/gt^; Vangl2^f/f^; Sftpc^CreER/+^; ROSA26^mTmG/+^* mice (n = 5 for each group). The percentage of large alveoli in *Vangl1^gt/gt^; Vangl2^f/f^; Sftpc^CreER/+^; ROSA26^mTmG/+^* lungs was reduced. All values are mean ± SEM. (\*) p\<0.05; (\*\*) p\<0.01; (\*\*\*) p\<0.001; ns, not significant (unpaired Student's *t*-test).](elife-53688-fig6){#fig6}

Disruption of the actomyosin cytoskeleton in alveolar type I cells in the absence of PCP signaling raised the possibility that AT1 cells failed to undergo morphogenetic adjustment to sheathe myofibroblasts and capillaries during secondary septa formation. Indeed, immunohistochemical analysis revealed slender *Vangl2*-deficient AT1 cells that failed to fold up to encase myofibroblasts ([Figure 6C and E](#fig6){ref-type="fig"}). This observation was further validated by TEM studies of control and *Vangl2^f/f^; Sox9^Cre/+^* lungs. For instance, AT1 cells in control lungs at P3 displayed folding to sheathe myofibroblasts that had migrated to the prospective sites of secondary septa formation ([Figure 1C](#fig1){ref-type="fig"}). By contrast, such coordinated morphological changes in AT1 cells did not occur in the mutant lungs ([Figure 1C](#fig1){ref-type="fig"}). These results imply an active role of AT1 cells in secondary septation likely through cell shape change, which would complement the action of myofibroblast migration and contraction in this highly coordinated process.

Taken together, we conclude that PCP signaling operates in both the lung epithelium and mesenchyme and control distinct aspects of cellular properties in each compartment necessary for alveologenesis. This includes ligand secretion, cell shape change and migration.

Alveolar type I cells lacking VANGL1/2 are compromised in alveolosphere formation {#s2-11}
---------------------------------------------------------------------------------

To further investigate the role of AT1 cells in alveolar formation, we adopted the alveolosphere assay ([@bib5]) and examined the cellular behavior of control and *Vangl1/2*-deficient alveolar cells in spheroid formation. This organoid system retains many important aspects of alveolar formation and would reveal the intrinsic cellular defects in AT1 cells during alveologenesis ([@bib6]). In this assay, fibroblasts/myofibroblasts are in direct contact with AT1 cells and obviate the need of PDGF-mediated migration.

We isolated alveolar type II cells (GFP^+^) from *Sftpc^CreER/+^; ROSA26^mTmG/+^* mice ([@bib37]; [@bib45]) by fluorescence-activated cell sorting (FACS). Tamoxifen was injected into *Sftpc^CreER/+^; ROSA26^mTmG/+^* mice to activate Sftpc^CreER^ and label SPC^+^ AT2 cells with GFP. Sorted alveolar type II cells were mixed with fibroblasts and cultured in 3D. In this process, AT2 (SPC^+^) cells proliferated and differentiated into AT1 (HOPX^+^) cells. After two weeks, lung organoids formed, in which alveolus-like structures expressing markers for alveolar type I cells were produced from alveolar type II cells in the presence of fibroblasts ([Figure 6G and H](#fig6){ref-type="fig"}). We performed a similar experiment using *Vangl1/2*-deficient AT2 cells purified from *Vangl1^gt/gt^; Vangl2^f/f^; Sftpc^CreER/+^; ROSA26^mTmG/+^* mice that had been administered with tamoxifen to delete *Vangl2* in SPC^+^ AT2 cells and in all AT1 cells originated from AT2 cells. In the absence of *Vangl1/2*, differentiation of AT2 cells and proliferation of AT2 and AT1 cells were unaffected. However, although a similar number of alveolospheres was obtained, the size distribution of the alveolospheres derived from *Vangl1/2*-deficient AT1 cells was dominated by those with a smaller size ([Figure 6G and H](#fig6){ref-type="fig"}). In control spheres, HOPX^+^ AT1 cells are located inside the spheres and are surrounded by SPC^+^ AT2 cells. This organization was not observed in spheres, in particular, medium and small alveolospheres, derived from *Vangl1/2*-deficient cells. This is consistent with defective cellular properties in *Vangl1/2*-deficient AT1 cells required for morphogenesis.

To assess the role of AT1 cells in alveologenesis, we generated *Vangl1^gt/gt^; Vangl2^f/f^; Aqp5^CreER/+^* mice and administered tamoxifen to these animals at P2. Activation of CreER by tamoxifen in Aquaporin 5 (AQP5)^+^ cells induced *Vangl2* removal in AT1 cells. Analysis of lungs at P7 revealed areas of defective alveolar development due to loss of *Vangl1/2* ([Figure 6I](#fig6){ref-type="fig"}). This suggests a vital function of *Vangl1/2* in alveolar type I cells during alveologenesis. Together, our results support a central role of *Vangl1/2* in controlling the cellular behavior of AT1 cells during alveolar formation.

Loss of *Vangl1/2* in alveolar type I cells impairs their ability to form new alveoli following lung injury {#s2-12}
-----------------------------------------------------------------------------------------------------------

To further assess the function of *Vangl1/2* in AT1 cells during alveolar formation, we took advantage of the observation that bleomycin applied to adult mouse lungs induces formation of new alveoli ([@bib69]; [@bib43]; [@bib20]). In this setting, in response to bleomycin-induced loss of alveoli and fibrosis, alveolar type II cells produce alveolar type I cells, which contribute to new alveoli and lung repair in mice. This feature provided an ideal setup for testing how loss of *Vangl1/2* in AT1 cells affects their ability in alveolar formation. To this end, we generated *Sftpc^CreER/+^; ROSA26^mTmG/+^* (control) and *Vangl1^gt/gt^; Vangl2^f/f^; Sftpc^CreER/+^; ROSA26^mTmG/+^* adult mice and injected them with tamoxifen to inactivate *Vangl2* in alveolar type II cells, which were also labeled by GFP (from the *ROSA26^mTmG^* locus). Alveolar type I cells produced from alveolar type II cells would also be lineage-labeled by GFP. We then subjected these animals to bleomycin following the standard protocol. After 4 weeks post-bleomycin administration, lung repair was extensive in control lungs and newly formed alveoli had replaced the damaged lung tissues ([Figure 6J and K](#fig6){ref-type="fig"}). By contrast, fewer GFP^+^ alveoli in *Vangl1^gt/gt^; Vangl2^f/f^; Sftpc^CreER/+^; ROSA26^mTmG/+^* mice were found and they failed to reach the same size as that in control lungs ([Figure 6J and K](#fig6){ref-type="fig"}, [Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}). This suggests that *Vangl1/2*-deficient AT1 cells were compromised in their ability to form new alveoli although *Vangl1/2*-deficient AT2 cells could also contribute to the observed defects in alveolar repair. While additional studies are required, these findings suggest a critical role of *Vangl1/2* in controlling the cellular behavior of alveolar type I (and/or type II) cells during alveolar formation.

COPD patients have reduced levels of *WNT5A* and *VANGL2* expression {#s2-13}
--------------------------------------------------------------------

To explore whether studies of PCP signaling in alveolar formation in mice recapitulate human diseases, we assessed PCP signaling in lung tissues of COPD/emphysema patients ([Figure 7A and B](#fig7){ref-type="fig"}). We found that the expression levels of *WNT5A* and *VANGL2* were reduced ([Figure 7C](#fig7){ref-type="fig"}), suggesting a link between PCP signaling and alveolar loss/regeneration in these patients. This finding is consistent with other studies in the literature, in which *VANGL2* expression was reported to be downregulated in a small cohort of COPD patient lungs ([@bib52]). In addition, polymorphisms of human *VANGL2* have been associated with negative smoking impacts on lung function in humans ([@bib52]).

![The WNT--VANGL axis is downregulated in the lungs of human emphysema patients.\
(**A**) Hematoxylin and eosin-stained lung sections of normal and emphysema patients. Characteristic disruption of alveoli was observed in emphysema patients, resulting in increased airspace. (**B**) Elastin staining of lung sections of normal and emphysema patients. The slides were counterstained with tartrazine. Elastin, which was detected at the secondary septa in normal lungs (arrows), was greatly reduced in the lungs of emphysema patients. (**C**) qPCR analysis of *VANGL1, VANGL2 and WNT5A* in lungs from normal and emphysema patients (n = 12 for each group). The mRNA levels of *VANGL2* and *WNT5A* were significantly reduced in emphysema patients. All values are mean ± SEM. (\*) p\<0.05; (\*\*) p\<0.01; (\*\*\*) p\<0.001; ns, not significant (unpaired Student's *t*-test). (**D**) A new model of alveolar formation through control of cellular properties by PCP signaling. We propose that epithelial PCP signaling via the *Wnt5a--Ror2--Vangl2* axis (colored green) controls PDGF secretion from alveolar type I and type II cells to promote proliferation of mesenchymal fibroblasts. In this process, a positive feedback loop between WNT5A and PDGF leads to expansion of the fibroblast pool required for subsequent alveologenesis. The expanded fibroblast population expresses SMA and becomes myofibroblasts, which continue to proliferate. In addition, myofibroblasts migrate to the prospective site of secondary septation in response to PCP signaling (colored blue). Likewise, epithelial PCP signaling (colored green) instructs cell shape changes of alveolar type I cells necessary for encasing myofibroblasts that migrate toward the site of secondary septation. All of these cellular events (orange-colored boxes) are due to modulation of the actomyosin cytoskeleton via the *Wnt5a--Ror2--Vangl2* axis.](elife-53688-fig7){#fig7}

It is interesting to note that SERPINA3 (a protease inhibitor), SAA3 (serum amyloid A) and CD14, whose expression was increased in *Vangl2*-deficient murine lungs ([Figure 4E](#fig4){ref-type="fig"}), are activated in COPD patients and are biomarkers for COPD ([@bib9]; [@bib74]; [@bib68]). This supports the idea that the PCP pathway is compromised in COPD patients and may contribute to their inability to form new alveoli.

Taken together, our studies have provided new mechanistic insight into alveolar formation and PCP signaling ([Figure 7D](#fig7){ref-type="fig"}). They also form the basis for future work to understand how different signaling pathways are integrated during alveologenesis in development and following injury.

Discussion {#s3}
==========

Our studies have addressed a central question in alveolar development, the molecular basis of secondary septa formation ([Figure 7D](#fig7){ref-type="fig"}). Through genetic and molecular approaches, we decipher PCP signaling through a *Wnt5a--Ror2--Vangl2* axis as a key element in mediating cell-cell interactions between alveolar cells (type I and type II) and myofibroblasts. The PCP pathway controls PDGF signaling from alveolar type I and II cells to fibroblasts/myofibroblasts to promote their proliferation. This essential step ensures the production an adequate number of fibroblasts/myofibroblasts required for alveologenesis. A positive feedback loop between WNT5A and PDGF facilitates expansion of fibroblasts/myofibroblasts. Subsequently, orchestrated movement between alveolar type I cells and myofibroblasts is regulated by PCP signaling, including cell shape change of alveolar type I cells and migration of myofibroblasts. As a result, they come in close proximity to each other and undergo coordinated morphogenesis to produce secondary septa and alveoli. In this process, myofibroblasts also send out cellular processes to form a network that likely functionally connects alveoli. These critical events require changes in cellular properties mediated by PCP signaling and reflect a novel facet of PCP function. We speculate that this new insight can serve as a paradigm for understanding PCP function in other tissues beyond the classical tissue polarity. Moreover, our findings suggest that the developmental programs executed by PCP are utilized for tissue repair in the lung. This establishes the foundation for elucidating disease mechanisms of BPD and COPD caused by alveolar loss.

Genetic and molecular analyses of *Wnt5a*, *Ror2* and *Vangl2*-deficient lungs demonstrate a critical role of these PCP components in controlling the actomyosin cytoskeleton, which underlies ligand secretion/delivery, and cell migration and interaction during secondary septa formation. Surprisingly, these processes do not appear to involve the classical tissue polarity, in which asymmetric distribution of PCP components is associated with polarization of cells ([@bib49]). Instead, the primary function of the *Wnt5a--Ror2--Vangl2* axis is to modulate the cellular properties of lung cells required for alveolar formation. Thus, while the PCP pathway functions in many cellular processes that rely on the actomyosin cytoskeleton, our studies revealed that PCP activity is not confined to tissue polarity. Our work shows that PCP signaling exerts its effects at the subcellular levels via controlling the cytoskeleton in alveolar type I, type II cells and myofibroblasts. This notion is consistent with studies that reported a purported function of PCP in axonal guidance ([@bib79]) or postsynaptic compartmentalization ([@bib46]), in which PCP was proposed to also operate at the subcellular level. Moreover, our findings suggest that the PCP pathway controls important cellular processes beyond epithelial layers as demonstrated by the involvement of PCP signaling in myofibroblast migration. Hence, our investigation establishes novel modes of PCP function in tissue patterning. We anticipate that additional cellular processes that utilize similar modes of PCP signaling as reported here will be uncovered in other tissues.

Loss of *Ror2* in either lung epithelium or mesenchyme recapitulates phenotypes due to lack of *Vangl2*. This supports a crucial role of ROR2 in activating VANGL2 and downstream events. However, we cannot rule out the possibility that a Fz receptor ([@bib70]) is also involved in relaying the WNT5A signal to VANGL2. In this case, Fz and ROR2 would cooperate in a non-redundant manner to transduce the WNT5A signal. Identifying the putative Fz receptor and elucidating its functions would significantly increase our understanding of the signaling cascade that regulates secondary septa formation.

Our genetic and molecular studies support a new model in which morphological changes of AT1 cells induced by PCP signaling are required for secondary septa elongation. An active role of AT1 cells in secondary septation contrasts their passive role implied from the existing models in which myofibroblasts drive secondary septa formation. Nevertheless, further studies are required to define the functional consequence of PCP signaling in AT1 cells and delineate the relative contributions of AT1 and AT2 cells to alveologenesis. We also showed that morphological changes in myofibroblasts are also critical for secondary septa formation. Thus, secondary septa development relies on coordinated cell shape changes in both alveolar epithelial cells and myofibroblasts. A key element in this process is an altered actomyosin cytoskeleton controlled by the *Wnt5a--Ror2--Vangl2* axis. How this axis is integrated with other regulators of the cytoskeleton requires further investigations. We also do not have the cellular resolution to discern the exact sequence of events. This would rely on improved microscopy and the ability to image lung slices for an extended period of time. New culture conditions are also needed to recapitulate alveolar formation in ex vivo lung explants or lung slices. Future development of fluorescent probes that enable monitoring lung development in vivo would be an important step forward to validate these models.

In this study, we have focused on AT1/2 cells and myofibroblasts in secondary septa formation. A third component of the secondary septa is endothelial cells. It is unclear whether PCP signaling controls capillary morphogenesis during alveolar development. This would require additional genetic and molecular studies, similar to those described in this work. Interestingly, PCP signaling has been implicated in network organization of vessels in other organs ([@bib61]).

Our analysis of *Vangl2*-deficient lungs revealed that PDGF ligands produced in alveolar cells fail to signal to myofibroblasts. Our data point to defective delivery of the PDGF ligand due to disrupted cytoskeleton in the absence of PCP signaling. Additional cell biological and biochemical studies are required to pinpoint the defects in PDGFA trafficking in alveolar type I and type II cells. We propose that PDGF signal reception is compromised by loss of cell-cell contacts between alveolar cells and mesenchymal myofibroblasts. Further validation of this model would require direct visualization of ligand--receptor interactions on juxtaposed membranes between ligand-producing and --receiving cells, for instance, using split GFP technology ([@bib21]) where GFP signal is reconstituted at sites of ligand--receptor contact. An alternative possibility of cell-cell contacts between alveolar cells and mesenchymal myofibroblasts involves actin-based filopodia. This is similar to the cytonemes described in other systems including the mouse limb ([@bib59]). The function of cytonemes has been debated but recent data show that they are required for mediating ligand-receptor signaling for major signaling pathways in lieu of diffusion ([@bib57]; [@bib29]). Cytonemes originate from ligand-producing and receptor-producing cells, but cytonemes have not been reported in lung cells likely due to technical issues.

In conclusion, our work has provided key new insights into the cellular and molecular basis of secondary septation and alveolar formation. Moreover, we have revealed a novel mode of PCP signaling beyond tissue polarity. These studies set the stage for further investigation to obtain a complete mechanistic understanding of alveolar development and repair.

Materials and methods {#s4}
=====================

Animal husbandry {#s4-1}
----------------

Mouse strains used in this study are listed in the Key Resources table ([Supplementary file 1](#supp1){ref-type="supplementary-material"}). Matings were set up to obtain mice with the indicated genotypes described in this study. This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The Institutional Animal Care and Use Committee (IACUC) at the University of California, San Francisco, approved all experiments performed in this study (protocol \#AN173680-03).

Generation of *Aqp5^CreER^* mice {#s4-2}
--------------------------------

To produce the *Aqp5^CreER^* mouse line, the translational start ATG in the mouse *Aqp5* genomic locus was replaced with a CreER-FRT-PGK-Neo-FRT cassette though gene targeting in E14 embryonic (ES) cells. The FRT-PGK-Neo-FRT cassette was subsequently removed by crosses with *FLPe* mice ([@bib54]).

Histology and immunohistochemistry {#s4-3}
----------------------------------

Mouse lungs were dissected at the indicated time points and fixed in 4% paraformaldehyde (PFA) in PBS on ice for 1 hr. Tissues were embedded in paraffin wax or OCT (frozen sections) and sectioned at 7 μm. Thick sections were prepared in a similar manner. Histological analysis, such as hematoxylin and eosin (H&E) staining, was performed as described ([@bib38]).

Elastin fiber staining was performed following Hart\'s staining method with minor modifications. Lung sections were deparaffinized with xylene, rehydrated with ethanol and water, and then placed in the working solution (10% Weigert\'s iron resorcin-fuchsin stock solution, 2% HCl and 70% ethanol) overnight at room temperature. After three washes in water, the sections were counterstained in 0.5% tartrazine/0.5% acetic acid for 3 min. Sections were rinsed three times in water and dehydrated with ethanol and xylene. The elastin fibers were stained black.

Immunohistochemistry was performed following standard procedures ([@bib38]). Antibodies used in this study are listed in the Key Resources table ([Supplementary file 1](#supp1){ref-type="supplementary-material"}). The following primary antibodies were used for paraffin wax sections: rabbit anti-NKX2.1 (1:100, Epitomics), chicken anti-GFP (1:200, abcam), goat anti-CC10 (1:200, Santa Cruz Biotechnology), rabbit anti-prosurfactant protein C (proSP-C) (1:200, MilliporeSigma), hamster anti-T1α (1:200, Developmental Studies Hybridoma Bank), mouse anti-HOPX (1:100, Santa Cruz Biotechnology), and rabbit anti-phospho-AKT (Ser473) (1:150, Cell Signaling Technology). The following primary antibodies were used for frozen sections: rat anti-E-cadherin (1:200, Invitrogen), chicken anti-GFP (1:300, abcam), mouse anti-ACTA2 (1:200, Thermo Scientific Lab Vision), rat anti-PECAM-1 (CD31) (1:150, Santa Cruz Biotechnology), rabbit anti-PDGFRA (1:150, Cell Signaling Technology), rabbit anti-phospho-PDGFRA (Tyr754) (1:100, Cell Signaling Technology), rabbit anti-Cofilin (1:150, Cell Signaling Technology), rabbit anti-phospho-Cofilin (Ser3) (1:100, Cell Signaling Technology), rabbit anti-phospho-LIMK1 (Thr508)/LIMK2 (Thr505) (1:100, Cell Signaling Technology), and rat anti-VANGL2 (1:150, MilliporeSigma). Secondary antibodies and conjugates used were donkey anti-rabbit Alexa Fluor 488 or 594 (1:1000, Life Technologies), donkey anti-goat Alexa Fluor 488, donkey anti-chicken Alexa Fluor 488 or 647 (1:1000, Life Technologies), donkey anti-mouse Alexa Fluor 488 or 594 (1:1000, Life Technologies), and donkey anti-rat Alexa Fluor 594 (1:1000, Life Technologies). For biotinylated secondary antibodies, goat anti-hamster (1:1000, Jackson ImmunoResearch Laboratories), donkey anti-rabbit (1:1000, Jackson ImmunoResearch Laboratories), donkey anti-rat (1:1000, Jackson ImmunoResearch Laboratories) and horse anti-mouse (1:1000, Jackson ImmunoResearch Laboratories) were used. The signal was detected using streptavidin-conjugated Alexa Fluor 488, 594, or 647 (1:1000, Life Technologies). For antibodies against PDGFRA, phospho-PDGFRA (Tyr754), phospho-Cofilin (Ser3), phospho-AKT, phospho-LIMK1 (Thr508)/LIMK2 (Thr505) and VANGL2, instead of using streptavidin-conjugated Alexa Fluor 488, 594, or 647 as the tertiary antibody, HRP-conjugated streptavidin (1:1000, Perkin-Elmer) was used in combination with fluorogenic substrate Alexa Fluor 594 tyramide for 30 s (1:200, TSA kit; Perkin Elmer). F-actin was stained with rhodamine-conjugated phalloidin (1:200; Sigma).

For determining VANGL2 localization and distribution in the lung, frozen sections (at 20 and 50 μm) were prepared from the lungs of *Sox9^Cre/+^; ROSA26^mTmG/+^* and *Pdgfra^CreER/+^; ROSA26^mTmG/+^* mice. Sections were incubated with chicken anti-GFP and rat anti-VANGL2 at 4°C overnight. Donkey anti-chicken Alexa Fluor 488 and biotinylated donkey anti-rat secondary antibodies were incubated at 4°C overnight. Streptavidin-conjugated HRP tertiary antibody was incubated at room temperature for 2 hr to detect the VANGL2 signal.

For visualizing PDGFA localization and distribution in the lung, lungs from *Pdgfa^ex4COIN/+^; Sox2^Cre/+^* mice at P2 were collected and fixed in 4% PFA on ice for 1 hr. Lungs were washed in 0.02% NP40 in PBS for 2 hr, and placed in X-gal staining solution (5 mM K~3~Fe(CN)~6~, 5 mM K~4~Fe(CN)~6~, 2 mM MgCl~2~, 0.01% sodium deoxycholate, 0.02% NP-40, 1 mg/ml X-gal) for 16 hr at 37°C. LacZ-stained lungs were paraffin embedded and sectioned. Immunohistochemistry was subsequently performed on LacZ-stained sections using antibodies against HOPX (AT1 cell marker) and SPC (AT2 cell marker).

Images for H&E staining, elastin staining and LacZ staining were taken using a SPOT 2.3 CCD camera connected to a Nikon Eclipse E1000 microscope. Confocal images were captured on a Leica SPE laser-scanning confocal microscope. Adjustment of red/green/blue/grey histograms and channel merges were performed using LAS AF Lite (Leica Microsystems).

Transmission electron microscopy (TEM) {#s4-4}
--------------------------------------

Lungs from *Vangl2^f/f^; Sox9^Cre/+^* mice and their littermate controls were infused with EM fixative (2% glutaraldehyde and 4% paraformaldehyde in PBS) through the trachea. Dissected lungs were immersed in ice-cold EM fixative for at least 2 hr. The samples were trimmed to 1 mm cubes and sectioned at 0.1 μm. The ultrathin sections were placed on copper grids and post-stained. Grids were viewed and photographed with a JEOL JEM-1400 Transmission Electron Microscope at the Cell Sciences Imaging Facility at Stanford University.

Measurement of the mean linear intercept (MLI) {#s4-5}
----------------------------------------------

The mean linear intercept (MLI) (Lm) was measured according to the previously reported methods ([@bib47]) with minor modification. In brief, for each animal 15 fields of hematoxylin and eosin-stained lung sections from three different slides were imaged at 20x magnification using a Nikon Eclipse E1000 Microscope. Fields that contained visible blood vessels or airways were excluded. A grid with 10 horizontal and 10 vertical lines was superimposed on the images using ImageJ. The number of times that the alveolar walls (the primary and secondary septa) intercepted the grid lines was counted. Lm was calculated using the following equation: Lm = (Lh + Lv)/m, where Lh is the total length of horizontal line, Lv is the total length of vertical line, and m is the total number of intercepts.

Cell proliferation assays {#s4-6}
-------------------------

The rate of cell proliferation was determined through a short pulse of EdU labeling ([@bib38]). Briefly, mouse pups at postnatal day 0, 2, 5 and 7 were intraperitoneally injected with 0.25 mg of EdU (50 μl of EdU/PBS solution at 5 mg/ml) and lungs were collected 1 hr following EdU injection. Assessment of EdU incorporation was performed on paraffin-embedded lung sections using the Click-iT EdU Alexa Fluor 488 Imaging Kit (Life Technologies). These lung sections were co-stained with antibodies against NKX2.1 or GFP.

For quantifying proliferation of alveolar fibroblasts and myofibroblasts, proliferating cells were labeled by EdU while fibroblasts/myofibroblasts were distinguished by H2BGFP expressed from the *Pdgfra* locus (the *Pdgfra^H2BGFP^* allele). The proliferation rate of alveolar fibroblasts/myofibroblasts was calculated as the ratio of (EdU^+^H2BGFP^+^ cells)/(H2BGFP^+^ cells).

Alternatively, alveolar fibroblasts and myofibroblasts were identified by anti-PDGFRA antibodies. In this case, the proliferation rate of alveolar fibroblasts/myofibroblasts was calculated as the ratio of (EdU^+^PDGFRA^+^ cells)/(PDGFRA^+^ cells).

Proximity Ligation In Situ Hybridization (PLISH) {#s4-7}
------------------------------------------------

In situ hybridization was performed following the procedure of Proximity Ligation In Situ Hybridization (PLISH) ([@bib47]) with minor modifications. Lungs from *Pdgfra^H2BGFP/+^* mice were dissected and fixed in 4% paraformaldehyde overnight and embedded in OCT for frozen sections at 16 μm. Lung sections were incubated with H probe pairs, which were targeted to the adjacent positions in a tiled manner along the mRNA of interest. Nine H probe pairs for mouse *Wnt5a* and ten H probe pairs for mouse *Ror2* were used (see [Supplementary file 2](#supp2){ref-type="supplementary-material"}). In the circularization reaction, the barcode sequences in the paired probes hybridized to the \'bridge\' (phosphorylated VB02) and \'circle\' (phosphorylated CCC2.1) oligonucleotides to form a closed circle, which underwent rolling circle replication to generate a long single-stranded amplicon of tandem repeats. Fluorescently-labeled oligonucleotides were hybridized to the complementary tandem repeats and generated bright puncta for visualization.

For combined in situ hybridization/immunohistochemistry, samples were washed 3 times in PBST (0.05% Tween-20 and 5 mM EDTA in PBS) after PLISH and incubated in blocking buffer (3% BSA, 0.1% Triton X-100 and 5 mM EDTA in PBS) for 30 min. The sections were then incubated with primary antibodies (goat anti-CC10 or chicken anti-GFP in blocking buffer) for 2 hr at room temperature, washed in PBST and then incubated with secondary antibodies (donkey anti-goat Alexa Fluor 488 or donkey anti-chicken Alexa Fluor 488) for 1 hr at room temperature.

Lentivirus production and transduction {#s4-8}
--------------------------------------

cDNAs encoding PDGFA-3xFLAG and PDGFA-eGFP fusions were cloned into the modified pSECC lentiviral vector. The mouse PDGFA (NM_008808.4) coding sequence was amplified from mouse P3 lung cDNA library.

Lentiviruses were produced in HEK293T cells grown in DMEM containing 10% FBS, 1x penicillin/streptomycin and 1x L-glutamine. One day before transfection, HEK293T cells were seeded at 50--60% confluence in a 6 cm dish; cells reached 80--90% confluence for transfection the following day. For HEK293T cells on one 6 cm dish, 1 μg of pMD2.G, 1 μg of psPAX2 and 2 μg of the plasmid of interest (PDGFA-3xFLAG or PDGFA-eGFP) were mixed in 500 μl OPTI-MEM and 30 μl of polyethylenimine (PEI) (1 μg/μl, transfection reagent) was added. Media were replaced 24 hr post-transfection and viral supernatants were harvested 48 hr post-transfection. The viral supernatants were filtered through 0.45 μm PVDF filters and then added to control and *Vangl1^gt/gt^; Vangl2^--/--^* adherent mouse cells together with 8 μg/ml polybrene. 12 hr after transduction, the media were replaced with regular culture media (DMEM with 10% FBS and 1% penicillin/streptomycin).

PDGFA secretion assay {#s4-9}
---------------------

Control and *Vangl1^gt/gt^; Vangl2^--/--^* cells were derived from mouse embryos at 13.5 and 18.5 *dpc*, authenticated by methods such as PCR and STR profiling, and tested negative for mycoplasma contamination. Loss of *Vangl1/2* ensures a complete removal of signaling through VANGL1/2, These cell lines were lentivirally transduced with constructs that expressed 3xFLAG-tagged PDGFA as described above. Cells were seeded onto 6 cm dishes. Once cells reached 100% confluence, the media were replaced with OPTI-MEM supplemented with insulin, transferrin and selenium (ITS) and cells were cultured for another 16 hr. The supernatants were then collected and filtered through 0.45 μm filters. Protein inhibitor cocktails were added to the filtrates, which were centrifuged at high speed (\>12000 rpm) for 15 min at 4° to remove cell debris and protein aggregates. The filtrates were further concentrated in protein concentration columns (Millipore CENTRICON YM-10 Centrifugal Filter Unit 2 mL 10 kDa) through centrifugation at 2000 g for 1 hr at 4°C. In parallel, cells on the 6 cm dishes were scraped for lysis. Immunoprecipitation (IP) buffer (50 mM Tris pH 7.4, 2 mM EDTA, 150 mM NaCl, 0.5% Triton X-100, 1x protein inhibitor cocktail) was added to the concentrated filtrates or scraped cells in a total volume of 500 μl. Immunoprecipitation was performed using FLAG-M2 beads following standard procedures. SDS-PAGE sample buffer was added to the immunoprecipitates for western blot analysis. PDGFA secretion was calculated using the following equation: P~secretion~ = P~s~/(P~s~ + P~c~) where P~s~ = PDGFA in supernatant/medium, P~c~ = PDGFA in the cell lysate.

Alveolosphere assays {#s4-10}
--------------------

Alveolosphere assays were performed as previously described ([@bib5]) with minor modifications. Briefly, *Sftpc^CreER/+^; ROSA26^mTmG/+^* and *Vangl1^gt/gt^; Vangl2^f/f^; Sftpc^CreER/+^; ROSA26^mTmG/+^* mice were injected with tamoxifen to label alveolar type II (AT2) cells with eGFP. One month post-tamoxifen injection, lungs were dissected and digested in dispase (1.2 U/ml), collagenase B (0.5 mg/ml) together with 50 U/ml DNase at 37°C. After incubation for 1 hr, an equal volume of sorting media (phenol red free DMEM with 2% FBS and 2% penicillin/streptomycin) was added to the dissociated cells. The mixture was then passed through 70 μm cell strainers and centrifuged at 600 g for 10 min. Cell pellets were resuspended in 3 ml RBC lysis buffer (Invitrogen) for 2 min on ice and 5 ml sorting medium was added. The mixture was passed through the 40 μm cell strainer. After centrifugation at 600 g for 10 min, cell pellets were resuspended in 1 ml sorting buffer for fluorescence-activated cell sorting (FACS). eGFP-labeled AT2 cells were isolated using a BD FACSAria III sorter. 5 × 10^3^ sorted AT2 cells and 5 × 10^4^ Mlg 2908 cells (ATCC CCL-206, a lung fibroblast cell line) were added to 100 μl culture medium (DMEM/F12 supplemented with Glutamax, 10% FBS, 1x insulin/transferrin/selenium, 2x penicillin/streptomycin, 0.25 μg/ml Amphotericin B, 0.04 μg/ml EGF, 0.05 μg/ml bFGF, 0.02 μg/ml KGF, and 0.02 μg/ml HGF), mixed with an equal volume of Matrigel (BD Biosciences), and then seeded into a 0.4 μm Transwell insert (Corning) in a 24-well plate. The medium was replaced every two days. After three weeks of culture, the Transwell inserts were fixed in 4% paraformaldehyde at 4°C overnight and embedded in OCT. The organoid/Matrigel-containing inserts were sectioned at 50 μm for immunohistochemistry.

RNA-Seq analysis {#s4-11}
----------------

RNA-Seq was performed as previously described ([@bib38]). In brief, the left lung lobe from control, *Vangl2^f/f^; Sox9^Cre/+^* and *Ror2^f/f;^ Sox9^Cre/+^* mice were homogenized in 1 ml TRIzol (Life Technologies) and 200 μl chloroform was then added. After centrifugation, the upper aqueous layer was removed and mixed with an equal volume of 70% ethanol. RNA was extracted with the RNeasy Mini Kit (Qiagen) following the manufacturer's instructions. RNA quality was evaluated using the Agilent 2100 Bioanalyzer. Samples were sequenced on an Illumina HiSeq 2000 or HiSeq4000. Functional enrichment analysis was performed using Ingenuity Pathway Analysis software (version 7.1). Differential gene expression and gene ontology (GO) enrichment analyses were performed with RStudio. The barplot of gene ontology enrichment was created in order to visualize differentially expressed genes that are associated with a certain biological process (BP). Datasets have been deposited in NCBI's Gene Expression Omnibus database and are accessible through GEO Series accession number GSE140779.

qPCR analysis {#s4-12}
-------------

RNAs extracted from lung tissues were reverse-transcribed with the Maxima First Strand cDNA Synthesis Kit (Thermo Scientific). Quantitative PCR (qPCR) was carried out on the ABI Prism 7900HT Sequence Detection System. Primers for qPCR are listed in the Sequence-based reagent table.

Cell migration (wound recovery or healing) assay {#s4-13}
------------------------------------------------

The migratory capacity of lung myofibroblasts was determined using the Culture-Insert 2 Well system (ibidi). Briefly, lungs from control and *Vangl2^f/f^; Pdgfra^Cre/+^* mice at P3 were dissected and digested in dispase (1.2 U/ml) and collagenase B (0.5 mg/ml) at 37°C to release single cells. After incubation for 1 hr, an equal volume of culture medium (DMEM with 10% FBS and 2% penicillin/streptomycin) was added to dissociated cells. The mixture was then passed through a 40 μm cell strainer and centrifuged at 600 g for 10 min. Cell pellets were resuspended in 200 μl culture medium and seeded into wells (100 μl per well). Myofibroblasts were allowed to attach to fibronectin--coated plates for 2--3 hr. Non-adherent cells were washed out and myofibroblasts were cultured to reach 100% confluence in \~2--3 days. Confluent myofibroblasts were switched to starvation medium (DMEM with 0.2% FBS and 1% penicillin/streptomycin) for 16 hr prior to removal of the insert. Migration of myofibroblasts into the wounded area (insert) was allowed to continue for another 36--48 hr.

Human lung tissues {#s4-14}
------------------

Lung samples were obtained at the time of lung transplantation performed for severe emphysema (Global Initiative for Chronic Obstructive Lung Disease Criteria, stages III or IV) during the study period 2015‐2019. Control lung tissues were obtained from donor lungs not utilized for lung transplantation. Our studies indicate that these lungs are physiologically and pathologically normal ([@bib72]). Written informed consent was obtained from all subjects and the study was approved by the University of California, San Francisco Institutional Review Board (IRB approval \# 13--10738).

Statistical analysis {#s4-15}
--------------------

Both technical replicates and biological replicates (using different cell lines and mice) were performed. All results were presented as mean ± SEM. Two-tailed Student's *t*-tests were used to calculate the P values. Statistical significance was considered only when the P value was less than 0.05.
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Decision letter

Morrisey

Edward E

Reviewing Editor

University of Pennsylvania

United States

In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.

Thank you for submitting your article \"A *Wnt5a-Ror2-Vangl2* axis controls the cytoskeleton and confers cellular properties required for alveolar formation\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Edward Morrisey as the Senior Editor. The reviewers have opted to remain anonymous.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

As you will see, while the reviewers acknowledged the merits in your study, there were many concerns related to both lack of data for the conclusions made and the confusing manner in which the manuscript is organized. All of the reviewers felt that the current manuscript should be pared down to focus on the points that can be substantiated with data. Please note in particular the concerns raised by reviewer \#1 in relation to data needed to support the major conclusions of this manuscript.

Reviewer \#1:

In Zhang et al., the authors investigate the role of *Wnt5a-Ror2-Vangl2* in alveologenesis and alveoli injury repair. They show extensive data from both epithelium and mesenchymal knockouts of a number of genes in this pathway, as well as Pdgfa mutants. Multiple mechanisms have been implicated, including affecting cell signaling, morphology, migration, cell-cell junction, ER and Golgi morphology. The findings do demonstrate a role for *Wnt5a-Ror2-Vangl2* in alveologenesis. However, many of the conclusions on mechanisms are not well supported. There is lack of logic in the organization of the results, which jump from epithelium to mesenchyme and back, from bleomycin in mice and then to COPD patient samples.

1\) Throughout the paper, there is an overall paucity of quantification, of MLI, of protein expression level, etc.

2\) Figure 1---figure supplement 1, *Sox2*-Cre;*Vangl2* mutant was not really described in the text. Where is the cre active, and how results from this mutant fit in with the rest of the data is unclear.

3\) *Vangl1;2;Sox9^cre^* mutant, it will be informative to know lung phenotype, on whether the defects are in branching or sacculation.

4\) Why *Shh^cre^*, a robust cre, is unable to recombine *Vangl2*-fl is not explained. Is there a change in RT-PCR? Why is *Sox9^cre^* able to recombine *Vangl2*-fl but not *Shh^cre^*?

5\) Does inactivation of Porc in the epithelium lead to a defect?

6\) Figure 3E*Pdgfa* expression in AT1 and AT2 cells, not convincing.

7\) \"....levels of PDGFRa were unaffected (Figure 3G)\". However, by RNAseq, \"*Pdgfra* expression was downregulated.\" Discrepancy?

8\) The specificity of p-PDGFRa antibody needs to be demonstrated.

9\) Decrease in AKT signaling needs to be shown.

10\) The secretion assay, double null mutants were used. It is unclear what cells were isolated.

11\) Given that ER and Golgi are affected, is protein processing/secretion a general defect, or is PDGFA signal specifically affected?

12\) Figure 3J, 3L, need to show a field of cells before zooming in. Quantification is needed.

13\) The finding that *Vangl;Spc-^cre^* mutants showed simplification phenotype suggests that Vangl is required in AT2 cells. It does support that the phenotype is due to secretion defect, as concluded in subsection "Alveolar epithelial cells lacking *VANGL2* fail to present the PDGF ligand to mesenchymal myofibroblasts".

14\) Figure 3K, only show histology, not \"areas of defective alveolar development that was associated with loss of *Vangl1/2*\". Antibody staining is needed to link mosaic inactivation to regional phenotype.

15\) Subsection "Alveolar epithelial cells lacking *VANGL2* fail to present the PDGF ligand to mesenchymal myofibroblasts", unclear how the defect in cell contact is needed for PDGF secreted signaling.

16\) \"Conversely, loss of PDGF ligand resulted in depletion of WNT5A-producing fibroblasts/myofibroblasts. These results support a positive feedback loop between WNT5A and PDGFA...\" The staining shows in Pdgfa mutants the expression of PDGFRA expression. It does not show regulation of WNT5A. To demonstrate feedback, Wnt5a expression needs to be assayed in PDGF pathway mutants.

17\) Aside from in vitro migration assay, there is no other support for migration defect of Vangl mutants. Myofibroblast migration defects shown in *Pdgfa* mutant was found during sacculation stages. Is there an in vivo defect during sacculation of altered distribution of myofibroblasts?

18\) Figure 6A, it is unclear how AT1 that lack GFP, which presumably is not cre-recombined, show increase of p-Cofilin.

19\) To really demonstrate AT1 wrapping of other cell types, thick section and 3D rendition is needed.

20\) In the smaller spheres, are there fewer cells, or smaller AT1 cells?

21\) For bleomycin experiment, het mutant control needs to be used. What is the phenotype on fibrosis?

22\) It is not clear why fibrosis was studied in mouse, but COPD was studied in patients.

Reviewer \#2:

In the manuscript, \"A *Wnt5a-Ror2-Vangl2* axis controls the cytoskeleton and confers cellular properties required for alveolar formation\" by Kuan Zhang and colleagues, the authors examine the role of the planar cell polarity (PCP) pathway in alveologenesis. The authors identify a *Wnt5a-Ror2-Vangl2* cascade that involves PDGF secretion from alveolar type I and type II cells, and results in cell shape changes of type I cells and migration of myofibroblasts due to changes in the cytoskeleton.

The studies presented in the manuscript are comprehensive, well-designed and presented, and provide novel insights into the role of the PCP pathway in alveologenesis. These findings are an important and useful addition to the field. However, there are several issues that could be addressed prior to publication.

1\) It is interesting that the *Shh-Cre* did not result in deletion of *Vangl2*, particularly given that the authors appear to show excellent recombination of the *ROSA26-mTmG* allele, and that is Cre is known to be strongly expressed in the lung epithelium. Do the authors have any explanation why?

2\) Although SOX9 is well known to be expressed in the distal lung epithelium during development, it is also expressed in the lung mesenchyme. Because the authors use the SOX9-Cre to characterize the effects of epithelial-specific loss of *Vangl2*, they should provide (ideally quantitative) data about the degree of recombination that the *Sox9-Cre* induces in the lung mesenchyme. One straight forward way to do this would be to add data using their *Sox9-Cre;ROSA26-mTmG* mice co-stained with a pan-epithelial marker such as *Cdh1* or *Nkx2-1*. Significant recombination in the mesenchyme could significantly impact the interpretation of their data.

3\) Why did the authors choose to use the *Sox2*-*Cre* when they were primarily interested in the distal epithelium (Figure 3E) -- why not just stick with the *Sox9-Cre* (especially since these data are shown in the next panel, Figure 3F)

4\) I don\'t understand the rationale for using whole-lung as the samples for RNA-Seq instead of FACS-sorted cells, especially when the authors had *Sox9-Cre;ROSA26-mTmG;Vangl2* mice available, which would of easily permitted isolation of epithelial (and if desired, separate mesenchymal) cell population for RNA-Seq. The problem with a whole-lung bulk-seq analysis in this case, particularly when the authors have showed that epithelial loss of *Vangl2* results in decreased proliferation in the mesenchyme is that the differential expressed gene list will be dramatically skewed by the alterations in cell types. I don\'t think the authors necessarily need to re-do these experiments for publication, but they should significantly limit the conclusions that they draw from these data. FACS-sorted cell populations or scRNA-Seq would have been preferred.

5\) In Figure 1---figure supplement 4, the alveoli appear somewhat compressed for P7-P30, particular P12-P30. Are these samples inflation-fixed? If not, this would be ideal, as this will impact the appearance of the alveolar structure, especially the relative thinness or thickness, as is trying to be illustrated. This may impact the authors' conclusion about how the relative thinness/thickness changes throughout alveolar development.

6\) The organoid data are somewhat difficult to interpret and doesn\'t seem to add much to the paper, but probably no harm in showing it either. While the organoids appear to be smaller, none of the organoid data provides any direct evidence why this would be. The fact that AT1 and AT proliferation appeared to be unaffected is probably the most useful observation. It may be worth just showing this directly in their knockout mouse model.

7\) Although the authors showed that AT1 and AT2 cell proliferation seemed to be unaffected following loss of VANGL1/VANGL2, it is probably a bit of a stretch (without additional data) that the reason for the impaired lung regeneration following bleomycin injury with *Vangl1/Vangl2* deletion induced by *SPC-^Cre^-ERT2* is an AT1 mediated defect.

Reviewer \#3:

This is a very timely and informative work. The authors have done a great and quite extensive analysis of the role of Wnt5a in the lung. The results will be of general interest and citable by other investigators in the field.

There are some problems:

1\) The manuscript is unnecessarily extensive and diffused. The authors have piled up a vast amount of experimental designs some of which were just negative findings that lead them to the next set of studies, which turned out to be positive. The authors need to cull these extra data out of the manuscript and make it cogent as the alternative (the present form) reduces the impact of their findings.

2\) The bulk of the genetic experiments used conventional knockout models. To be able to use the title that refers to alveologenesis, the authors had the option of using conditional (temporal) KO models, or they will have to show that the phenotypes they observe is not due to secondary causes of early development caused by the KO. This requires examining the KO mice in the embryonic stage.

Aletrnativel the authors may choose to change the title.

3\) If no \"No obvious difference in the gross morphology of the lungs was noticed between control and *Vangl2^f/f^;Sox9^Cre/+^*mice prior to postnatal day 3\" what was the reason for death on PN2?

4\) The authors claim that Vangl1 plays a minor role in

alveolar formation and loss of Vangl1 is compensated by *Vangl2* in alveologenesis\". As these were conventional KO mice, how can the authors know that Vangl1 has a role in alveolar formation?

5\) It is interesting, as the authors state, that a small number of *Vangl2^f/f^; Sox9^Cre/+^* mice survived beyond postnatal day 7.\" What was the histology of these lungs?

6\) In *Vangl2^f/f^; Sox9^Cre/+^* embryos, is there a phenotype?

7\) In the studies using cells from control and *Vangl1/2*-deficient cells, what type of cells were isolated and how?

8\) Figure 3E is supposed to show the level of PDGFA (LacZ). But, B-gal staining is not quantifiable. Nor is there an apparent significant difference.

9\) In the bleo model in which *Vangl1/2*-deficient AT1 cells were compromised in their ability to form new alveoli, the authors should use a quantifying method such as MLI in areas of destroyed alveoli.

10\) The authors state: \"We noticed that the primary septa in control lungs became visibly thinner during the first three days of postnatal life likely due to flattening of AT1 cells\". Better and more convincing data would be required to include here.

\[Editors\' note: further revisions were suggested prior to acceptance, as described below.\]

Thank you for resubmitting your work entitled \"A mammalian *Wnt5a-Ror2-Vangl2* axis controls the cytoskeleton and confers cellular properties required for alveologenesis\" for further consideration by *eLife*. Your revised article has been evaluated by Edward Morrisey (Senior Editor) and a Reviewing Editor.

The manuscript has been improved but there are some remaining issues that need to be addressed before acceptance, as outlined below:

We ask that you revise the text of your manuscript to more accurately describe your results. As reviewer 2 has noted, there are several unsubstantiated claims and unclear descriptions of some of your experiments. While we do not anticipate additional experiments are required to address these issues, please be advised that accuracy and rigor are important hallmarks of all *eLife* papers.

Reviewer \#1:

The authors made a tremendous effort in revision. The study is much improved and is now suitable for publication.

Reviewer \#2:

In their manuscript \"A mammalian *Wnt5a-Ror2-Vangl2* axis controls the cytoskeleton and confers cellular properties required for alveologenesis\", Dr. Zhang and colleagues present exciting and timely data from their studies of the role of PCP signaling during alveologenesis. In response to reviewers, they have made a number of significant improvements to the manuscript, including the additional of substantial new data. However, the manuscript itself continues to be limited by a number of conclusions that are either over-stated or not well supported by the data, and benefits from further revision.

1\) Given the mortality timeline described in the manuscript, including some long-term survivors, in *Sox9 ^Cre^/wt; Vangl2 ^f/f^* mice, the addition of a Kaplan-Meier survival curve would be more robust than a text description of their observations.

2\) The authors state that the \"initial expansion of fibroblasts/myofibroblasts was unaffected (Figure 5A)\" (in *Pdgfra ^Cre^/wt; Vangl2 ^f/f^* mice) and that \"the primary role of mesenchymal PCP signaling is to control myofibroblast migration and function.\" In Figure 5A, while there appears to be no affect on proliferation of these cells at P3, there is a dramatic reduction in the number of EdU^+^ cells at P5.

3\) The authors state that \"abnormal myofibroblast development first appeared on day 2...\" What exactly do they mean by this? If it's decreased proliferation then this should be stated. If they mean something else, then the data to support it should be directly referenced.

4\) The authors state (in regards to the mesenchymal conditional knock-out of Porcupine), that \"these results support the notion that non-canonical Wnt signaling in the lung mesenchyme initiate PCP signaling for alveolar development.\" Although the paper as a whole presents a variety of data that supports this concept, the manuscript contains a number of statements like this over-interpreting individual experiments. As the authors themselves state, porcupine is required for the release of all Wnt ligands, so this particular experiment does not differentiate between the roles of canonical and non-canonical Wnt signaling in alveolar development.

5\) Similarly, from the same set of experiments the authors conclude that there is \"no effect on differentiation of AECs.\" The only data presented to support this statement are two images from T1a/SPC double-stains of wild-type versus conditional KO lungs. At most, from these data you could say that there was no obvious difference in the number of type 1 and type 2 AECs, but even that statement would require counting cell numbers across a number of animals and sections.

6\) The inclusion of the SPC conditional knockout seems out of place. The rest of the manuscript focuses on type 1 AECs, so these data do not seem to add much to an already long manuscript.

7\) In the earlier portion of the manuscript, the authors focus on conditional knockouts of *Vangl2* in various cellular compartments, but then for the intracellular trafficking studies, used cells derived from *Vangl1^gt/gt^; Vangl2^-/-^* embryos. Why was the double-knockout studied instead cells deficient in Vangl2 only? Did the *Vangl2* deficient cells not have the same phenotype?

8\) The images shown do not really seem to support the conclusion that PGFA-GFP is trapped within the ER. In Figure 3J, the PDGFA expression seems to be in a fairly uniform peri-nuclear distribution (not in the same punctate loci as the ER stain), and in the images in Figure 3---figure supplement 4 the PDGFA seems to just be uniformly distributed through the cytoplasm rather than \"trapped in the ER.\"

9\) Although I don\'t think there is anything wrong with the RNA-Seq data presented, I think is value to the manuscript continues to be significantly limited by the fact that it is derived from whole lung tissue in a knockout where the authors have already shown has dramatic alterations in the ratios of certain cell populations (e.g. depletion of myofibroblasts). In this situation, the conclusions that can be drawn a gene ontology analysis of these data are very limited (the GO categories will largely represent biological functions of cell populations that are enriched or depleted in the cKO relative to control). It really adds little to the data already presented in the paper, and doesn\'t really address the question that set out to answer with the experiment (e.g. \"...to reveal the pathways controlled by epithelial PCP signaling.\").

10\) The manuscript could benefit from more clarity about what the authors think is happening in their injury model. Looking at the two images shown in Figure 6---figure supplement 1, the airspaces appear to be larger. However, the measured MLI for the conditional knockout is smaller. Do the authors think the alveoli are smaller after injury? If so, why? Also, their conclusions that \"AT1 cells were compromised in their ability to form new alveoli\" is a dramatic over-interpretation of these data, particularly given that the *Sftpc-^CreER^* driver was used. While I agree there definitely appears to be an affect on injury repair, whether the defect is with type 1 or type 2 AECs or both, and what exactly the defect is remains entirely unclear.

11\) Again, the organoid data are intriguing but I\'m not sure how much it really adds to the story. I suppose it supports the general concept that *Vangl2* is required for general cellular organization, but again exactly what is happening is pretty difficult to really understand.

Reviewer \#3:

This was a work that in my first review, I found to be very timely and significant. I was impressed by the number of approaches and the volume of the obtained data. I had concerns about the way the data were presented. The authors have rewritten the manuscript and it is now in much shape. I also had concern as to whether the authors were actually examining the process of alveologenesis or rather the events prior to it that ultimately lead to defects in this process.

The authors have responded to my concerns and I am satisfied with their response. They have additionally added data that strengthens their conclusions. I am still not absolutely convinced that their findings are directly relevant to postnatal alveologenesis, but I admit this is splitting hair. So, all in all, I think the manuscript represents high quality multidimensional data that make it meritorious for dissemination to the field. The work will definitely have an impact on our understanding of alveologenesis.

10.7554/eLife.53688.sa2

Author response

> Reviewer \#1:
>
> 1\) Throughout the paper, there is an overall paucity of quantification, of MLI, of protein expression level, etc.

In response to the reviewer's comment, we have added quantification of MLI (*e.g.*, in Figures 1, 2, 6, and in figure supplements), of protein expression levels (*e.g.*, in Figure 3), etc. We also would like to point out it is not practical to use Western blots to quantify protein expression for this purpose. For instance, PDGFRA is expressed in airway smooth muscle cells, vascular smooth muscle cells and alveolar myofibroblasts. The mutants we study in this manuscript selectively affect alveolar myofibroblasts. Thus, western blots of the whole lungs will not reveal changes in PDGFRA in these mutants. Also, there is no easy way to sort alveolar myofibroblasts away from airway smooth muscle cells and vascular smooth muscle cells for protein analysis. As a result, we have relied on quantification of immunoreactivity (*e.g.*, PDGFA, PDGFRA) in individual lung cells.

> 2\) Figure 1---figure supplement 1, Sox2-cre;Vangl2 mutant was not really described in the text. Where is the cre active, and how results from this mutant fit in with the rest of the data is unclear.

*Sox2-Cre* is known to induce recombination in all epiblasts by embryonic (E) day 6.5 and has been used to generate the null mutant from a floxed allele. In this regard, *Vangl2^f/f^; Sox2^Cre/+^* is effectively *Vangl2^--/--^*. This provides an important tool to test the validity of VANGL2 antibodies. In fact, several commercially available VANGL2 antibodies we have tested yielded identical signals between control and *Vangl2^--/--^* lungs.

> 3\) Vangl1;2;Sox9^cre^ mutant, it will be informative to know lung phenotype, on whether the defects are in branching or sacculation.

*Vangl1/2; Sox9-Cre* mutant lungs display no apparent defects in branching or sacculation. This information is now included in Figure 1---figure supplement 3.

> 4\) Why Shh^cre^, a robust cre, is unable to recombine Vangl2-fl is not explained. Is there a change in RT-PCR? Why is Sox9^cre^ able to recombine Vangl2-fl but not Shh^cre^?

We were also surprised that *Shh-Cre*, which is broadly expressed and widely used, was unable to effectively remove VANGL2 in the lung. We observed the presence of *Vangl2^--^* (null; converted from *Vangl2^f^* by *Shh-Cre*) by PCR but only a few cells in the proximal airway lost VANGL2 (Figure 1---figure supplement 4) and thus no phenotypes were observed. We do not know why *Sox9-Cre* was more effective than *Shh-Cre* in converting *Vangl2^f^* to *Vangl2^--^*. Perhaps, this is related to the relatively large distance between the two loxP sites in *Vangl2^f^* and a higher level of Cre expression is required. We also won\'t be surprised if *Shh-Cre* is unable to effectively convert other floxed alleles.

> 5\) Does inactivation of Porc in the epithelium lead to a defect?

We have utilized *Sox9-Cre, Shh-Cre* and *Nkx2.1-Cre* to inactivate *Porcn* and generated *Pornc^f/f^; Sox9^Cre/+^; Pornc^f/f^; Shh^Cre/+^* and *Pornc^f/f^; Nkx2.1^Cre/+^* mice. *Pornc^f/f^; Sox9^Cre/+^* mice died soon after birth due to craniofacial defects but lung branching appeared to be normal. *Pornc^f/f^; Shh^Cre/+^* and *Pornc^f/f^; Nkx2.1^Cre/+^* mice survived after birth without apparent branching or alveolar defects. These results suggest that inactivation of epithelial *Porcn* does not lead to a defect.

> 6\) Figure 3E Pdgfa expression in AT1 and AT2 cells, not convincing.

We have quantified PDGFA expression in AT1 and AT2 cells (Figure 3E). More AT1 cells expressed a higher level of PDGFA than AT2 cells.

> 7\) \"...levels of PDGFRa were unaffected (Figure 3G)\". However, by RNAseq, \"Pdgfra expression was downregulated.\" Discrepancy?

Downregulation of *Pdgfra* expression by bulk RNA-Seq primarily reflects the reduced number of myofibroblasts in the mutant lungs (Figure 3C). However, the level of PDGFRA in individual myofibroblasts was unaffected (Figure 3G), implying that *Pdgfra* transcription at the single cell level was unaltered.

> 8\) The specificity of p-PDGFRa antibody needs to be demonstrated.

We have added data (in Figure 3---figure supplement 2) to demonstrate the specificity of p-PDGFRA. We showed that p-PDGFRA displayed a similar expression pattern to that of PDGFRa since both co-localized with SMA in both airway smooth muscle cells and alveolar myofibroblasts. In *Pdgfa^--/--^* lungs, myofibroblasts were lost and p-PDGFRA immunoreactivity also disappeared. This confirmed the specificity of p-PDGFRA on lung tissues. Of note, p-PDGFRA antibodies only worked on frozen sections with TSA amplification.

> 9\) Decrease in AKT signaling needs to be shown.

This piece of information has been added to Figure 3---figure supplement 3.

> 10\) The secretion assay, double null mutants were used. It is unclear what cells were isolated.

We have employed two types of cells, one from E13.5 mouse embryonic fibroblasts and another from E18.5 lung fibroblasts.

> 11\) Given that ER and Golgi are affected, is protein processing/secretion a general defect, or is PDGFA signal specifically affected?

We noticed that the amount of secreted proteins (normalized to the cell number) from *Vangl1/2* mutant cells was reduced compared to controls. This suggests a general defect in protein processing/secretion in the absence of *Vangl1/2*.

> 12\) Figure 3J, 3L, need to show a field of cells before zooming in. Quantification is needed.

We have included images of a field of cells in Figure 3---figure supplement 4. Quantification of the percentage of high and low PDGFA-expressing cells is shown in Figure 3---figure supplement 4.

> 13\) The finding that Vangl;Spc-^cre^ mutants showed simplification phenotype suggests that Vangl is required in AT2 cells. It does support that the phenotype is due to secretion defect, as concluded in subsection "Alveolar epithelial cells lacking VANGL2 fail to present the PDGF ligand to mesenchymal myofibroblasts".

Indeed, the in vivo phenotypes in *Vangl1/2/Sftpc^CreER^* mutant lungs and the secretion defect in *Vangl1/2*-deficient cells support a model in which defective PDGFA secretion underlies the alveolar phenotype. However, we cannot rule out the possibility that other secreted ligands also contribute to the alveolar phenotype.

> 14\) Figure 3K, only show histology, not \"areas of defective alveolar development that was associated with loss of Vangl1/2\". Antibody staining is needed to link mosaic inactivation to regional phenotype.

We have added this piece of data to Figure 3---figure supplement 5.

> 15\) Subsection "Alveolar epithelial cells lacking VANGL2 fail to present the PDGF ligand to mesenchymal myofibroblasts", unclear how the defect in cell contact is needed for PDGF secreted signaling.

There is evidence to suggest that cell-cell contact is required for signal transduction of several major signaling pathways. This could serve to deliver ligands directly to their receptors on the cell surface of responsive cells. Whether this is a universal phenomenon is unclear. In this regard, we do not have additional mechanistic insight into how loss of cell contact could affect PDGF signaling.

> 16\) \"Conversely, loss of PDGF ligand resulted in depletion of WNT5A-producing fibroblasts/myofibroblasts. These results support a positive feedback loop between WNT5A and PDGFA...\" The staining shows in Pdgfa mutants the expression of PDGFRA expression. It does not show regulation of WNT5A. To demonstrate feedback, Wnt5a expression needs to be assayed in PDGF pathway mutants.

We have added qPCR analysis of *Wnt5a* in the revision; *Wnt5a* expression was reduced in *Pdgfa* knockout lungs (Figure 3---figure supplement 8). This further supports our model in which PDGF signaling preserves a pool of *Wnt5a*-expressing myofibroblasts.

> 17\) Aside from in vitro migration assay, there is no other support for migration defect of Vangl mutants. Myofibroblast migration defects shown in Pdgfa mutant was found during sacculation stages. Is there an in vivo defect during sacculation of altered distribution of myofibroblasts?

We have added analysis of fibroblast/myofibroblast distribution in *Vangl2^f/f^; Pdgfra^Cre/+^* lungs at P0 and P5 (Figure 5D). We found no difference in the distribution of PDGFRA^+^ fibroblasts at P0. However, at P5 while PDGFRA^+^/SMA^+^ myofibroblasts had migrated to the prospective sites of secondary septa in control lungs, PDGFRA^+^/SMA^+^ cells in the mutant lungs stayed in the primary septa.

> 18\) Figure 6A, it is unclear how AT1 that lack GFP, which presumably is not cre-recombined, show increase of p-Cofilin.

In fact, AT1 cells in the original Figure 6A had weak GFP expression. Nevertheless, to avoid confusion, we have replaced the original images with new ones that show stronger GFP expression in AT1 cells.

> 19\) To really demonstrate AT1 wrapping of other cell types, thick section and 3D rendition is needed.

As suggested by the reviewer, we have used thick sections and 3D rendition to show AT1 wrapping of other cell types (Figure 6C, 6E).

> 20\) In the smaller spheres, are there fewer cells, or smaller AT1 cells?

We placed the same number of cells onto each insert at the beginning of the experiment. The smaller spheres contain fewer cells derived from either control or *Vangl1/2*-deficient lungs. In control spheres, HOPX^+^ AT1 cells are located inside the spheres and are surrounded by SPC^+^ AT2 cells. This organization was not observed in spheres, in particular medium and small alveolospheres, derived from *Vangl1/2*-deficient cells. This is consistent with defective cellular properties in *Vangl1/2*-deficient AT1 cells required for morphogenesis.

> 21\) For bleomycin experiment, het mutant control needs to be used. What is the phenotype on fibrosis?

Since het mutant (for *Vang2^f^)* and wild-type mice showed a similar response to bleomycin, we did not show both. Fibrosis occurred in control and *Vangl1/2*-deficient lungs and resolution of fibrosis took longer in the absence of *Vangl1/2*.

> 22\) It is not clear why fibrosis was studied in mouse, but COPD was studied in patients.

Bleomycin-induced lung injury is traditionally used as a model of lung fibrosis. Perhaps, less publicized is the fact that this model also offers an opportunity to assess alveolar repair following bleomycin-induced alveolar loss. We have exploited this aspect of the bleomycin model in this manuscript and showed that loss of *Vangl1/2* compromises alveolar repair. In this context, our mouse studies have direct relevance to our findings that COPD patients displayed reduced levels of PCP pathway components. We have clarified these points in the revised manuscript.

> Reviewer \#2:
>
> 1\) It is interesting that the Shh-Cre did not result in deletion of Vangl2, particularly given that the authors appear to show excellent recombination of the ROSA26-mTmG allele, and that is Cre is known to be strongly expressed in the lung epithelium. Do the authors have any explanation why?

We were also surprised that *Shh-Cre*, which is broadly expressed and widely used, was unable to effectively remove VANGL2 in the lung. The *ROSA26^mTmG^* allele is known to undergo recombination by even low levels of Cre activity; GFP was efficiently induced from the *ROSA26^mTmG^* allele by *Shh-Cre*. We observed the presence of *Vangl2^--^* (null; converted from *Vangl2^f^* by *Shh-Cre*) by PCR but only a few cells in the proximal airway had lost VANGL2 (Figure 1---figure supplement 4) and thus no phenotypes were observed. We do not know why *Sox9-Cre* was more effective than *Shh-Cre* in converting *Vangl2^f^* to *Vangl2^--^*. Perhaps, this is related to the relatively large distance between the two loxP sites in *Vangl2^f^* and a higher level of Cre expression is required. We also won\'t be surprised if *Shh-Cre* is unable to effectively convert other floxed alleles.

> 2\) Although SOX9 is well known to be expressed in the distal lung epithelium during development, it is also expressed in the lung mesenchyme. Because the authors use the SOX9-Cre to characterize the effects of epithelial-specific loss of Vangl2, they should provide (ideally quantitative) data about the degree of recombination that the Sox9-Cre induces in the lung mesenchyme. One straight forward way to do this would be to add data using their Sox9-Cre;ROSA26-mTmG mice co-stained with a pan-epithelial marker such as Cdh1 or Nkx2-1. Significant recombination in the mesenchyme could significantly impact the interpretation of their data.

We have included data on analysis of *Sox9^Cre/+^; ROSA26^mTmG^/^+^* lungs in Figure 1---figure supplement 3. We found that GFP induced by *Sox9-Cre* was not found in the mesenchyme of the distal lung and was detected in few scattered mesenchymal cells in the large airway. The only place where a substantial number of mesenchymal cells expressed GFP was the trachea. This piece of information in conjunction with the alveolar phenotype induced by *Sftpc^CreER^* or *Aqp5^CreER^* support our model in which epithelial *Vangl1/2* plays a key role in controlling alveolar formation.

> 3\) Why did the authors choose to use the Sox2-Cre when they were primarily interested in the distal epithelium (Figure 3E) -- why not just stick with the Sox9-Cre (especially since these data are shown in the next panel, Figure 3F)

It turned out that *Sox9-Cre* was less efficient in inducing recombination of the *Pdgfa^ex4COIN^*allele than *Sox2-Cre*. In Figure 3E, we aimed to uncover the site and level of PDGFA expression in the lung and *Sox2-Cre* was more suitable for this purpose. As such, we were able to conclude that (1) PDGFA is expressed in both AT1 and AT2 cells and (2) not only more AT1 cells express PDGFA but AT1 cells also harbor higher levels of PDGFA than AT2 cells.

> 4\) I don\'t understand the rationale for using whole-lung as the samples for RNA-Seq instead of FACS-sorted cells, especially when the authors had Sox9-Cre;ROSA26-mTmG;Vangl2 mice available, which would of easily permitted isolation of epithelial (and if desired, separate mesenchymal) cell population for RNA-Seq. The problem with a whole-lung bulk-seq analysis in this case, particularly when the authors have showed that epithelial loss of Vangl2 results in decreased proliferation in the mesenchyme is that the differential expressed gene list will be dramatically skewed by the alterations in cell types. I don\'t think the authors necessarily need to re-do these experiments for publication, but they should significantly limit the conclusions that they draw from these data. FACS-sorted cell populations or scRNA-Seq would have been preferred.

We agree with the reviewer about the pitfalls of using the whole lung as the source for RNA-Seq and have limited the conclusions that we can draw from these data. In the future, we will sort epithelial cells for RNA-Seq. Ideally, we also would like to sort myofibroblasts for RNA-Seq. However, this is complicated by the fact that it would be difficult to sort myofibroblasts away from airway smooth muscle cells and vascular smooth muscle cells since they express a similar set of markers.

> 5\) In Figure 1---figure supplement 4, the alveoli appear somewhat compressed for P7-P30, particular P12-P30. Are these samples inflation-fixed? If not, this would be ideal, as this will impact the appearance of the alveolar structure, especially the relative thinness or thickness, as is trying to be illustrated. This may impact the authors' conclusion about how the relative thinness/thickness changes throughout alveolar development.

We did not inflate the lungs when we fixed the tissues except for those used for EM studies. We have provided quantification of the relative thickness of the primary septa at different stages of development in Figure 1---figure supplement 5 (the old Figure 1---figure supplement 4).

> 6\) The organoid data are somewhat difficult to interpret and doesn\'t seem to add much to the paper, but probably no harm in showing it either. While the organoids appear to be smaller, none of the organoid data provides any direct evidence why this would be. The fact that AT1 and AT proliferation appeared to be unaffected is probably the most useful observation. It may be worth just showing this directly in their knockout mouse model.

We agree with the reviewer that the organoid data added little insight into how *Vangl1/2* controls alveologenesis. The organoid system does not fully recapitulate alveologenesis in vivo. While AT1/2 proliferation does not seem to be affected in the organoids, AT1/2 proliferation was affected in mice. We should add that in control spheres, HOPX^+^ AT1 cells are located inside the spheres and are surrounded by SPC^+^ AT2 cells. This organization was not observed in spheres, in particular medium and small alveolospheres, derived from *Vangl1/2*-deficient cells. This is consistent with defective cellular properties in *Vangl1/2*-deficient AT1 cells required for morphogenesis.

> 7\) Although the authors showed that AT1 and AT2 cell proliferation seemed to be unaffected following loss of VANGL1/VANGL2, it is probably a bit of a stretch (without additional data) that the reason for the impaired lung regeneration following bleomycin injury with Vangl1/Vangl2 deletion induced by SPC-^Cre-ERT2^ is an AT1 mediated defect.

We agree with the reviewer that additional studies are required to elucidate the molecular basis of impaired alveolar repair in the absence of *Vangl1/2*. We have modified our description to acknowledge this point.

> Reviewer \#3:
>
> There are some problems:
>
> 1\) The manuscript is unnecessarily extensive and diffused. The authors have piled up a vast amount of experimental designs some of which were just negative findings that lead them to the next set of studies, which turned out to be positive. The authors need to cull these extra data out of the manuscript and make it cogent as the alternative (the present form) reduces the impact of their findings.

We have reorganized the manuscript and culled the extra data as much as possible as suggested by the reviewer. We have to admit that this manuscript delivers so many new points that there is no easy way to present them without giving the impression that some are out of place.

> 2\) The bulk of the genetic experiments used conventional knockout models. To be able to use the title that refers to alveologenesis, the authors had the option of using conditional (temporal) KO models, or they will have to show that the phenotypes they observe is not due to secondary causes of early development caused by the KO. This requires examining the KO mice in the embryonic stage.
>
> Alternatively the authors may choose to change the title.

In the original submission, we showed that postnatal removal of *Vangl2* by *Sftpc^CreER^* induced alveolar phenotypes (Figure 3K). In the revised manuscript, we have added analysis of alveolar phenotypes induced by postnatal removal of *Vangl2* via *Aqp5^CreER^* (Figure 6I). Together, these studies on conditional knockouts further support the conclusions from conventional knockouts.

> 3\) If no \"No obvious difference in the gross morphology of the lungs was noticed between control and Vangl2^f/f^;Sox9^Cre/+^ mice prior to postnatal day 3\" what was the reason for death on PN2?

In fact, there was no lethality at P2. Most of the *Vangl2^f/f^; Sox9^Cre/+^* mice died after P4/5. We have clarified this point in the revised manuscript. We should add that *Sox9^Cre^* exhibits extrapulmonary expression (Figure 1---figure supplement 3) and we cannot exclude the possibility that defects in other tissues may have contributed to the lethality.

> 4\) The authors claim that Vangl1 plays a minor role in alveolar formation and loss of Vangl1 is compensated by Vangl2 in alveologenesis\". As these were conventional KO mice, how can the authors know that Vangl1 has a role in alveolar formation?

We suggest that *Vangl1* plays a minor role in alveolar formation and loss of *Vangl1* is compensated by *Vangl2* in alveologenesis. This is based on the following observations: (1) *Vangl1^gt/gt^* mice have no apparent phenotypes; (2) *Vangl2^f/f^; Sox9^Cre/+^* mice display alveolar defects; (3) a fraction of *Vangl1^gt/+^; Vangl2^f/f^; Sox9^Cre/+^* mice exhibit more severe alveolar defects than *Vangl2^f/f^; Sox9^Cre/+^* mice; (4) no survivors beyond four weeks carry the genotype of *Vangl1^gt/+^; Vangl2^f/f^; Sox9^Cre/+^*. We also agree with the reviewer that a floxed allele of *Vangl1* is a better tool to define the role of *Vangl1* in alveologenesis. These points have been clarified in the revised manuscript.

> 5\) It is interesting, as the authors state, that a small number of Vangl2^f/f^; Sox9^Cre/+^ mice survived beyond postnatal day 7.\" What was the histology of these lungs?

Histology of the survivors was shown in Figure 1---figure supplement 6 of the original submission (Figure 1---figure supplement 7 in the revised manuscript). Alveolar defects were observed in the survivors although not as severe as those in the non-survivors. In the revision, we also showed that IL13 expression was increased in the mutant lungs, suggesting altered immune responses.

> 6\) In Vangl2^f/f^; Sox9^Cre/+^ embryos, is there a phenotype?

*Vangl2^f/f^; Sox9^Cre/+^* mutant lungs display no apparent defects in branching or sacculation. This information is now included in Figure 1---figure supplement 3.

> 7\) In the studies using cells from control and Vangl1/2-deficient cells, what type of cells were isolated and how?

We have employed two types of cells for these studies, one from E13.5 mouse embryonic fibroblasts and another from E18.5 lung fibroblasts.

> 8\) Figure 3E is supposed to show the level of PDGFA (LacZ). But, B-gal staining is not quantifiable. Nor is there an apparent significant difference.

The main purpose of Figure 3E was to show that PDGFA (LacZ) was expressed at a higher level in AT1 cells than AT2 cells, to which we have provided cell counting in the revision. Although β-gal staining is not indicative of the absolute level of PDGFA, staining on the same section does allow one to differentiate high expressers from low expressers.

Figure 3F showed that there is no apparent difference in PDGFA (LacZ) expression between control and *Vangl2^f/f^; Sox9^Cre/+^* lungs. We have added qPCR analysis of *Pdgfa* transcript levels in lungs of control and *Vangl2^f/f^; Sox9^Cre/+^* mice. There is no reduction (actually a slight increase) in *Pdgfa* mRNA levels in the mutant lungs.

> 9\) In the bleo model in which Vangl1/2-deficient AT1 cells were compromised in their ability to form new alveoli, the authors should use a quantifying method such as MLI in areas of destroyed alveoli.

We have included measurement of MLI in areas of destroyed alveoli in control and *Vangl1/2/Sftpc^CreER^* lungs (Figure 6---figure supplement 1). As expected, the MLI was reduced in the mutant lungs.

> 10\) The authors state: \"We noticed that the primary septa in control lungs became visibly thinner during the first three days of postnatal life likely due to flattening of AT1 cells\". Better and more convincing data would be required to include here.

We have provided quantification of the relative thickness of the primary septa at different stages of development in Figure 1---figure supplement 5 (the old Figure 1---figure supplement 4).

\[Editors\' note: further revisions were suggested prior to acceptance, as described below.\]

> We ask that you revise the text of your manuscript to more accurately describe your results. As reviewer 2 has noted, there are several unsubstantiated claims and unclear descriptions of some of your experiments. While we do not anticipate additional experiments are required to address these issues, please be advised that accuracy and rigor are important hallmarks of all eLife papers.
>
> Reviewer \#2:
>
> 1\) Given the mortality timeline described in the manuscript, including some long-term survivors, in Sox9 ^Cre^/wt; Vangl2 ^f/f^ mice, the addition of a Kaplan-Meier survival curve would be more robust than a text description of their observations.

We do not have an accurate count of mortality at different postnatal stages. Once *Vangl2^f/f^; Sox9^Cre/+^* mice had shown signs of sickness. They were collected for phenotypic and molecular analysis. We suspect that these mice could have lived for a few more days. Thus, our methodology does not allow us to generate an accurate survival curve. By contrast, most survivors did not display signs of sickness and were collected at a later stage. We were able to conclude that the percentage of survivors is small. For instance, in our study that spanned several years, 7 mice survived beyond P21, in comparison with 68 *Vangl2^f/f^; Sox9^Cre/+^* mice collected at or prior to P7.

> 2\) The authors state that the \"initial expansion of fibroblasts/myofibroblasts was unaffected (Figure 5A)\" (in Pdgfra ^Cre^/wt; Vangl2 ^f/f^ mice) and that \"the primary role of mesenchymal PCP signaling is to control myofibroblast migration and function.\" In Figure 5A, while there appears to be no affect on proliferation of these cells at P3, there is a dramatic reduction in the number of EdU^+^ cells at P5.

Fibroblasts/myofibroblasts from *Vangl2^f/f^; Pdgfra^Cre/+^* lungs did not show proliferative defects at P3 when expansion of fibroblasts/myofibroblasts occurred. Therefore, we stated that the initial expansion of fibroblasts/myofibroblasts was unaffected. This finding also implies that epithelial *Vangl2* plays a key role in the initial expansion of fibroblasts/myofibroblasts. By contrast, myofibroblast migration was affected in *Vangl2^f/f^; Pdgfra^Cre/+^* lungs, suggesting that the primary role of mesenchymal *Vangl2* is to control myofibroblast migration and function. Reduced myofibroblast proliferation was observed in *Vangl2^f/f^; Pdgfra^Cre/+^* lungs at P5 when myofibroblast migration was active and pervasive. This observation suggests that either mesenchymal *Vangl2* controls subsequent myofibroblast proliferation or the migration defect exerts a secondary effect on myofibroblast proliferation or both. We have clarified these points in the revised manuscript.

> 3\) The authors state that \"abnormal myofibroblast development first appeared on day 2...\" What exactly do they mean by this? If it's decreased proliferation then this should be stated. If they mean something else, then the data to support it should be directly referenced.

We have revised our statement to indicate that "decreased myofibroblast proliferation first appeared on day 2..."

> 4\) The authors state (in regards to the mesenchymal conditional knock-out of Porcupine), that \"these results support the notion that non-canonical Wnt signaling in the lung mesenchyme initiate PCP signaling for alveolar development.\" Although the paper as a whole presents a variety of data that supports this concept, the manuscript contains a number of statements like this over-interpreting individual experiments. As the authors themselves state, porcupine is required for the release of all Wnt ligands, so this particular experiment does not differentiate between the roles of canonical and non-canonical Wnt signaling in alveolar development.

As suggested by the reviewer, we have removed "non-canonical" in the revised manuscript.

> 5\) Similarly, from the same set of experiments the authors conclude that there is \"no effect on differentiation of AECs.\" The only data presented to support this statement are two images from T1a/SPC double-stains of wild-type versus conditional KO lungs. At most, from these data you could say that there was no obvious difference in the number of type 1 and type 2 AECs, but even that statement would require counting cell numbers across a number of animals and sections.

We have changed the statement to "...differentiation of alveolar type I and type II cells" as suggested by the reviewer.

> 6\) The inclusion of the SPC conditional knockout seems out of place. The rest of the manuscript focuses on type 1 AECs, so these data do not seem to add much to an already long manuscript.

We included the SPC conditional knockouts to support the involvement of type II AECs in alveolar formation and to respond to critiques from the other reviewers.

> 7\) In the earlier portion of the manuscript, the authors focus on conditional knockouts of Vangl2 in various cellular compartments, but then for the intracellular trafficking studies, used cells derived from Vangl1^gt/gt^; Vangl2^-/-^ embryos. Why was the double-knockout studied instead cells deficient in Vangl2 only? Did the Vangl2 deficient cells not have the same phenotype?

Our genetic studies suggest that *Vangl1* plays a minor role in alveolar formation (due to the presence of *Vangl2*). To ensure a complete removal of signaling through *Vangl1/2*, we only derived cells from *Vangl1^gt/gt^; Vangl2^--/--^* embryos.

> 8\) The images shown do not really seem to support the conclusion that PGFA-GFP is trapped within the ER. In Figure 3J, the PDGFA expression seems to be in a fairly uniform peri-nuclear distribution (not in the same punctate loci as the ER stain), and in the images in Figure 3---figure supplement 4 the PDGFA seems to just be uniformly distributed through the cytoplasm rather than \"trapped in the ER.\"

The reviewer is correct that ER trapping occurred in a significant fraction of but not all of *Vangl1/2*-deficient cells. We have removed "trapped in the ER" in the revised manuscript.

> 9\) Although I don\'t think there is anything wrong with the RNA-Seq data presented, I think is value to the manuscript continues to be significantly limited by the fact that it is derived from whole lung tissue in a knockout where the authors have already shown has dramatic alterations in the ratios of certain cell populations (e.g. depletion of myofibroblasts). In this situation, the conclusions that can be drawn a gene ontology analysis of these data are very limited (the GO categories will largely represent biological functions of cell populations that are enriched or depleted in the cKO relative to control). It really adds little to the data already presented in the paper, and doesn\'t really address the question that set out to answer with the experiment (e.g. \"...to reveal the pathways controlled by epithelial PCP signaling.\").

As suggested by the reviewer, we have deleted "To discover pathways that are affected by epithelial PCP signaling..." and also revised this section to indicate the limitation of RNA-Seq of whole lungs without cell sorting.

> 10\) The manuscript could benefit from more clarity about what the authors think is happening in their injury model. Looking at the two images shown in Figure 6---figure supplement 1, the airspaces appear to be larger. However, the measured MLI for the conditional knockout is smaller. Do the authors think the alveoli are smaller after injury? If so, why? Also, their conclusions that \"AT1 cells were compromised in their ability to form new alveoli\" is a dramatic over-interpretation of these data, particularly given that the Sftpc-^CreER^ driver was used. While I agree there definitely appears to be an affect on injury repair, whether the defect is with type 1 or type 2 AECs or both, and what exactly the defect is remains entirely unclear.

We should emphasize that the two images in Figure 6---figure supplement 1A were derived from mice that received tamoxifen treatment alone without bleomycin. The enlarged airspaces in *Vangl1^gt/gt^; Vangl2^f/f^; Sftpc^CreER/+^*lungs were due to removal of *Vangl1/2*. The MLI measurement in Figure 6---figure supplement 1B was conducted on mice that received both tamoxifen and bleomycin. The reduced MLI in *Vangl1^gt/gt^; Vangl2^f/f^; Sftpc^CreER/+^*lungs indicates a reduced distance between two primary or secondary septa in the regenerating alveoli, consistent with the definition of smaller alveoli. We suspect that smaller alveoli are related to alterations in the cytoskeleton in the absence of *Vangl1/2* but this notion would require additional investigation.

We have revised our statement to indicate that the observed effect on injury repair could be due to AT1 or AT2 or both.

> 11\) Again, the organoid data are intriguing but I\'m not sure how much it really adds to the story. I suppose it supports the general concept that Vangl2 is required for general cellular organization, but again exactly what is happening is pretty difficult to really understand.

We agree with the reviewer that the organoid data supports the general notion that the *Wnt5a--Ror2--Vangl2* axis is required for cellular organization. However, the molecular mechanism by which *Wnt5a--Ror2--Vangl2* signaling confers cellular properties requires additional studies, which are beyond the scope of this manuscript.
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